Selective	O
inhibition	O
of	O
interleukin-4	O
gene	O
expression	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
aspirin	O
.	O

Previous	O
studies	O
indicated	O
that	O
aspirin	O
(	O
acetylsalicylic	O
acid	O
[	O
ASA	O
]	O
)	O
can	O
have	O
profound	O
immunomodulatory	O
effects	O
by	O
regulating	O
cytokine	O
gene	O
expression	O
in	O
several	O
types	O
of	O
cells	O
.	O

This	O
study	O
is	O
the	O
first	O
in	O
which	O
concentrations	O
of	O
ASA	O
in	O
the	O
therapeutic	O
range	O
were	O
found	O
to	O
significantly	O
reduce	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
secretion	O
and	O
RNA	O
expression	O
in	O
freshly	B-cell_type
isolated	I-cell_type
and	I-cell_type
mitogen-primed	I-cell_type
human	I-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
,	O
ASA	O
did	O
not	O
affect	O
IL-13	B-protein
,	O
interferon-gamma	B-protein
,	O
and	O
IL-2	B-protein
expression	O
.	O

ASA	O
inhibited	O
IL-4	B-protein
,	O
but	O
not	O
IL-2	B-protein
,	O
promoter-driven	O
chloramphenicol	O
acetyltransferase	O
expression	O
in	O
transiently	O
transfected	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

The	O
structurally	O
unrelated	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
indomethacin	O
and	O
flurbiprofen	O
did	O
not	O
affect	O
cytokine	O
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
whereas	O
the	O
weak	O
cyclo-oxygenase	O
inhibitor	O
salicylic	O
acid	O
was	O
at	O
least	O
as	O
effective	O
as	O
ASA	O
in	O
inhibiting	O
IL-4	B-protein
expression	O
and	O
promoter	O
activity	O
.	O

The	O
inhibitory	O
effect	O
of	O
ASA	O
on	O
IL-4	O
transcription	O
was	O
not	O
mediated	O
by	O
decreased	O
nuclear	O
expression	O
of	O
the	O
known	O
salicylate	B-protein
target	I-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
and	O
was	O
accompanied	O
by	O
reduced	O
binding	O
of	O
an	O
inducible	O
factor	O
to	O
an	O
IL-4	B-DNA
promoter	I-DNA
region	I-DNA
upstream	O
of	O
,	O
but	O
not	O
overlapping	O
,	O
the	O
NF	B-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells-	I-DNA
and	I-DNA
NF-kappaB-binding	I-DNA
P1	I-DNA
element	I-DNA
.	O

It	O
is	O
concluded	O
that	O
anti-inflammatory	O
salicylates	O
,	O
by	O
means	O
of	O
a	O
previously	O
unrecognized	O
mechanism	O
of	O
action	O
,	O
can	O
influence	O
the	O
nature	O
of	O
adaptive	O
immune	O
responses	O
by	O
selectively	O
inhibiting	O
the	O
expression	O
of	O
IL-4	B-protein
,	O
a	O
critical	O
effector	O
of	O
these	O
responses	O
,	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IMMUNOBIOLOGY	NULL
Selective	NULL
imhibition	NULL
of	NULL
interleukin-4	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
by	NULL
aspirin	NULL
Antonella	NULL
Cianferoni	NULL
,	NULL
John	NULL
T.	NULL
Schroeder	NULL
,	NULL
Jean	NULL
Kim	NULL
,	NULL
John	NULL
W.	NULL
Schmidt	NULL
,	NULL
Lawrence	NULL
M.	NULL
Lichtenstein	NULL
,	NULL
Steve	NULL
N.	NULL
Georas	NULL
,	NULL
and	NULL
Vincenzo	NULL
Casolaro	NULL
Previous	NULL
studies	NULL
indicated	NULL
that	NULL
aspirin	NULL
(	NULL
acetylsalicylic	NULL
acid	NULL
[	NULL
ASA	NULL
]	NULL
)	NULL
can	NULL
have	NULL
profound	NULL
immunomodulatory	NULL
effects	NULL
by	NULL
regulating	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
several	NULL
types	NULL
of	NULL
cells	NULL
.	NULL

This	NULL
study	NULL
is	NULL
the	NULL
first	NULL
in	NULL
which	NULL
concentrations	NULL
of	NULL
ASA	NULL
in	NULL
the	NULL
therapeutic	NULL
range	NULL
were	NULL
found	NULL
to	NULL
significantly	NULL
reduce	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-4	NULL
secretion	NULL
and	NULL
RNA	NULL
expression	NULL
in	NULL
freshly	NULL
isolated	NULL
and	NULL
mitogen-primed	NULL
human	NULL
CD4+*	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
ASA	NULL
did	NULL
not	NULL
affect	NULL
IL-13	NULL
,	NULL
inter-feron-y	NULL
,	NULL
and	NULL
IL-2	NULL
expression	NULL
.	NULL

ASA	NULL
inhibited	NULL
IL-4	NULL
,	NULL
but	NULL
not	NULL
IL-2	NULL
,	NULL
promoter-driven	NULL
chloramphenicol	NULL
acetyltransferase	NULL
ex	NULL
pression	NULL
in	NULL
transiently	NULL
transfected	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
structurally	NULL
unrelated	NULL
nonsteroidal	NULL
anti-inflammatory	NULL
drugs	NULL
indomethacin	NULL
and	NULL
flurbiprofen	NULL
did	NULL
not	NULL
affect	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
the	NULL
weak	NULL
cyclo-oxygenase	NULL
inhibitor	NULL
salicylic	NULL
acid	NULL
was	NULL
at	NULL
least	NULL
as	NULL
effective	NULL
as	NULL
ASA	NULL
in	NULL
inhibiting	NULL
IL-4	NULL
expression	NULL
and	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
inhibitory	NULL
effect	NULL
of	NULL
ASA	NULL
on	NULL
IL-4	NULL
transcription	NULL
was	NULL
not	NULL
mediated	NULL
by	NULL
decreased	NULL
nuclear	NULL
expression	NULL
of	NULL
the	NULL
known	NULL
salicylate	NULL
target	NULL
nuclear	NULL
factor	NULL
(	NULL
NF	NULL
)	NULL
-	NULL
«	NULL
B	NULL
and	NULL
was	NULL
accompanied	NULL
by	NULL
reduced	NULL
binding	NULL
of	NULL
an	NULL
inducible	NULL
factor	NULL
to	NULL
an	NULL
IL-4	NULL
promoter	NULL
region	NULL
upstream	NULL
of	NULL
,	NULL
but	NULL
not	NULL
overlapping	NULL
,	NULL
the	NULL
NF	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
NF-kB-binding	NULL
P1	NULL
element	NULL
.	NULL

It	NULL
is	NULL
concluded	NULL
that	NULL
anti-inflammatory	NULL
salicylates	NULL
,	NULL
by	NULL
means	NULL
of	NULL
a	NULL
previously	NULL
unrecognized	NULL
mechanism	NULL
of	NULL
action	NULL
,	NULL
can	NULL
influence	NULL
the	NULL
nature	NULL
of	NULL
adaptive	NULL
immune	NULL
responses	NULL
by	NULL
selectively	NULL
inhibiting	NULL
the	NULL
expression	NULL
of	NULL
IL-4	NULL
,	NULL
a	NULL
critical	NULL
effector	NULL
of	NULL
these	NULL
responses	NULL
,	NULL
in	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
Blood	NULL
.	NULL

2001	NULL
;	NULL
97	NULL
:	NULL
1742-1749	NULL
)	NULL
©2001	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
Introduction	NULL
Aspirin	NULL
(	NULL
acetylsalicylic	NULL
acid	NULL
[	NULL
ASA	NULL
]	NULL
)	NULL
is	NULL
the	NULL
oldest	NULL
and	NULL
most	NULL
widely	NULL
used	NULL
nonsteroidal	NULL
anti-inflammatory	NULL
drug	NULL
(	NULL
NSAID	NULL
)	NULL
.	NULL

Although	NULL
several	NULL
other	NULL
classes	NULL
of	NULL
NSAIDs	NULL
have	NULL
become	NULL
available	NULL
since	NULL
the	NULL
introduction	NULL
of	NULL
ASA	NULL
in	NULL
1899	NULL
,	NULL
this	NULL
agent	NULL
and	NULL
structurally	NULL
related	NULL
salicylates	NULL
still	NULL
provide	NULL
the	NULL
mainstay	NULL
of	NULL
therapy	NULL
for	NULL
inflammatory	NULL
musculoskeletal	NULL
disorders	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
compounds	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
effective	NULL
in	NULL
the	NULL
management	NULL
and	NULL
prevention	NULL
of	NULL
an	NULL
increasingly	NULL
diverse	NULL
array	NULL
of	NULL
noninflammatory	NULL
conditions	NULL
,	NULL
including	NULL
coronary	NULL
and	NULL
cerebral	NULL
ischemia	NULL
and	NULL
gastrointestinal	NULL
cancer	NULL
.	NULL
``	NULL

Both	NULL
the	NULL
therapeutic	NULL
properties	NULL
of	NULL
NSAIDs	NULL
and	NULL
their	NULL
side	NULL
effects	NULL
have	NULL
been	NULL
ascribed	NULL
to	NULL
their	NULL
ability	NULL
to	NULL
inhibit	NULL
generation	NULL
of	NULL
prostaglandin	NULL
(	NULL
PG	NULL
)	NULL
and	NULL
thromboxane	NULL
by	NULL
interfering	NULL
with	NULL
the	NULL
intracellular	NULL
enzyme	NULL
cyclo-oxygenase	NULL
(	NULL
COX	NULL
)	NULL
.	NULL

It	NULL
is	NULL
widely	NULL
accepted	NULL
that	NULL
the	NULL
anti-inflammatory	NULL
actions	NULL
of	NULL
NSAIDs	NULL
are	NULL
mediated	NULL
by	NULL
inhibition	NULL
of	NULL
the	NULL
inducible	NULL
COX	NULL
isoform	NULL
COX-2	NULL
,	NULL
whereas	NULL
their	NULL
detrimental	NULL
effects	NULL
on	NULL
gastric	NULL
mucosa	NULL
viability	NULL
and	NULL
platelet	NULL
function	NULL
are	NULL
due	NULL
mostly	NULL
to	NULL
inhibition	NULL
of	NULL
COX-1.4	NULL
The	NULL
relative	NULL
effectiveness	NULL
of	NULL
several	NULL
NSAIDs	NULL
against	NULL
the	NULL
2	NULL
isozymes	NULL
varies	NULL
considerably	NULL
.	NULL
``	NULL

In	NULL
particular	NULL
,	NULL
although	NULL
ASA	NULL
is	NULL
a	NULL
relatively	NULL
effective	NULL
,	NULL
irreversible	NULL
inhibitor	NULL
of	NULL
COX-1	NULL
,	NULL
its	NULL
effects	NULL
on	NULL
COX-2	NULL
activity	NULL
are	NULL
negligible	NULL
.	NULL
``	NULL

This	NULL
probably	NULL
explains	NULL
why	NULL
higher	NULL
doses	NULL
of	NULL
ASA	NULL
are	NULL
required	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
chronic	NULL
inflammatory	NULL
diseases	NULL
than	NULL
are	NULL
sufficient	NULL
to	NULL
inhibit	NULL
PG	NULL
generation	NULL
in	NULL
different	NULL
experimental	NULL
models	NULL
in	NULL
vitro	NULL
.	NULL
``	NULL

However	NULL
,	NULL
the	NULL
in	NULL
vivo	NULL
anti-inflammatory	NULL
and	NULL
anticancer	NULL
activity	NULL
of	NULL
nonacetylated	NULL
salicylates	NULL
,	NULL
which	NULL
are	NULL
poor	NULL
overall	NULL
inhibitors	NULL
of	NULL
both	NULL
COX-1	NULL
and	NULL
COX-2	NULL
,	NULL
is	NULL
almost	NULL
superimposable	NULL
to	NULL
that	NULL
of	NULL
ASA	NULL
or	NULL
even	NULL
more	NULL
potent	NULL
NSAIDs	NULL
,	NULL
such	NULL
as	NULL
diclofenac	NULL
.	NULL
``	NULL

Indeed	NULL
,	NULL
given	NULL
the	NULL
short	NULL
serum	NULL
half-life	NULL
of	NULL
ASA	NULL
(	NULL
15	NULL
minutes	NULL
)	NULL
,	NULL
the	NULL
serum	NULL
concentra-	NULL
tions	NULL
of	NULL
salicylic	NULL
acid	NULL
(	NULL
SA	NULL
)	NULL
,	NULL
its	NULL
major	NULL
nonacetylated	NULL
metabolite	NULL
,	NULL
are	NULL
better	NULL
predictors	NULL
of	NULL
therapeutic	NULL
effectiveness	NULL
than	NULL
the	NULL
concentrations	NULL
of	NULL
ASA	NULL
itself	NULL
.	NULL
``	NULL

In	NULL
the	NULL
light	NULL
of	NULL
these	NULL
observations	NULL
,	NULL
it	NULL
has	NULL
been	NULL
speculated	NULL
that	NULL
inhibition	NULL
of	NULL
PG	NULL
production	NULL
can	NULL
not	NULL
fully	NULL
account	NULL
for	NULL
the	NULL
therapeutic	NULL
potential	NULL
of	NULL
ASA	NULL
and	NULL
related	NULL
salicylates	NULL
.	NULL
``	NULL

Indeed	NULL
,	NULL
several	NULL
studies	NULL
showed	NULL
that	NULL
these	NULL
compounds	NULL
have	NULL
a	NULL
spectrum	NULL
of	NULL
biochemical	NULL
and	NULL
pharmacologic	NULL
effects	NULL
that	NULL
are	NULL
not	NULL
related	NULL
to	NULL
COX	NULL
inhibition	NULL
and	NULL
not	NULL
shared	NULL
with	NULL
other	NULL
NSAIDs	NULL
.	NULL

*	NULL
``	NULL
A	NULL
major	NULL
finding	NULL
was	NULL
the	NULL
discovery	NULL
that	NULL
ASA	NULL
and	NULL
SA	NULL
can	NULL
interfere	NULL
with	NULL
the	NULL
activation	NULL
of	NULL
critical	NULL
transcription	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
nuclear	NULL
factor	NULL
(	NULL
NF	NULL
)	NULL
B	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
and	NULL
activator	NULL
protein	NULL
1	NULL
(	NULL
AP-1	NULL
)	NULL
.	NULL

``	NULL
°	NULL
On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
salicylates	NULL
were	NULL
reported	NULL
to	NULL
activate	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
and	NULL
enhance	NULL
interferon	NULL
(	NULL
IFN	NULL
)	NULL
signaling	NULL
.	NULL

``	NULL
``	NULL
``	NULL
*	NULL
``	NULL
``	NULL
These	NULL
overall	NULL
effects	NULL
of	NULL
salicylates	NULL
are	NULL
compounded	NULL
by	NULL
their	NULL
ability	NULL
to	NULL
induce	NULL
the	NULL
release	NULL
of	NULL
potent	NULL
anti-inflammatory	NULL
mediators	NULL
,	NULL
such	NULL
as	NULL
adeno-sine	NULL
and	NULL
15-epi-lipoxin	NULL
A	NULL
,	NULL
.	NULL

*	NULL
>	NULL
``	NULL
*	NULL
Taken	NULL
together	NULL
,	NULL
these	NULL
observations	NULL
support	NULL
the	NULL
idea	NULL
that	NULL
the	NULL
multiple	NULL
therapeutic	NULL
effects	NULL
of	NULL
ASA	NULL
derive	NULL
from	NULL
its	NULL
ability	NULL
to	NULL
regulate	NULL
a	NULL
network	NULL
of	NULL
biochemical	NULL
and	NULL
cellular	NULL
events	NULL
more	NULL
complex	NULL
than	NULL
was	NULL
initially	NULL
thought	NULL
.	NULL

It	NULL
has	NULL
long	NULL
been	NULL
speculated	NULL
that	NULL
the	NULL
effectiveness	NULL
of	NULL
ASA	NULL
in	NULL
chronic	NULL
inflammation	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
several	NULL
apparently	NULL
unrelated	NULL
clinical	NULL
conditions	NULL
,	NULL
might	NULL
be	NULL
at	NULL
least	NULL
partly	NULL
accounted	NULL
for	NULL
by	NULL
its	NULL
effects	NULL
on	NULL
immune	NULL
responses	NULL
.	NULL

!	NULL
``	NULL

However	NULL
,	NULL
data	NULL
on	NULL
this	NULL
issue	NULL
are	NULL
sparse	NULL
and	NULL
contradictory	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
few	NULL
studies	NULL
have	NULL
assessed	NULL
the	NULL
effects	NULL
of	NULL
ASA	NULL
or	NULL
other	NULL
NSAIDs	NULL
on	NULL
T-cell	NULL
differentiation	NULL
and	NULL
function	NULL
.	NULL

Decreased	NULL
production	NULL
of	NULL
immunomodulating	NULL
PGs	NULL
,	NULL
such	NULL
as	NULL
prostaglandin	NULL
E	NULL
;	NULL
(	NULL
PGE	NULL
)	NULL
,	NULL
in	NULL
accessory	NULL
cells	NULL
may	NULL
account	NULL
for	NULL
the	NULL
From	NULL
the	NULL
Departments	NULL
of	NULL
Medicine	NULL
and	NULL
Otolaryngology	NULL
,	NULL
The	NULL
Johns	NULL
Hopkins	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Baltimore	NULL
,	NULL
MD	NULL
.	NULL

Submitted	NULL
March	NULL
6	NULL
,	NULL
2000	NULL
;	NULL
accepted	NULL
October	NULL
27	NULL
,	NULL
2000	NULL
.	NULL

Supported	NULL
by	NULL
grants	NULL
Al41463	NULL
(	NULL
to	NULL
V.C	NULL
.	NULL
)	NULL

,	NULL
AI07290	NULL
(	NULL
to	NULL
L.M.L	NULL
.	NULL
)	NULL

,	NULL
and	NULL
AIO1152	NULL
(	NULL
to	NULL
S.N.G	NULL
.	NULL
)	NULL

from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

Reprints	NULL
:	NULL
Vincenzo	NULL
Casolaro	NULL
,	NULL
The	NULL
Johns	NULL
Hopkins	NULL
Asthma	NULL
&	NULL
Allergy	NULL
Center	NULL
,	NULL
1742	NULL
5501	NULL
Hopkins	NULL
Bayview	NULL
Circle	NULL
,	NULL
Baltimore	NULL
,	NULL
MD	NULL
21224	NULL
;	NULL
e-mail	NULL
:	NULL
casolaro	NULL
@	NULL
mail	NULL
.	NULL

jhmi.edu	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

Therefore	NULL
,	NULL
and	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
,	NULL
this	NULL
article	NULL
is	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
.	NULL

©2001	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
BLOOD	NULL
,	NULL
15	NULL
MARCH	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
6	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
15	NULL
MARCH	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
6	NULL
ability	NULL
of	NULL
ASA	NULL
and	NULL
other	NULL
NSAIDs	NULL
to	NULL
bolster	NULL
T	NULL
helper	NULL
(	NULL
Th	NULL
)	NULL
1-driven	NULL
cellular	NULL
immune	NULL
responses	NULL
.	NULL
``	NULL

''	NULL
``	NULL
ASA	NULL
and	NULL
ibuprofen	NULL
can	NULL
enhance	NULL
mitogen-induced	NULL
T-cell	NULL
proliferation	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
IFN-y	NULL
,	NULL
macrophage-derived	NULL
IL-1f3	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
,	NULL
and	NULL
IFN-	NULL
«	NULL
.	NULL

``	NULL
>	NULL
Conversely	NULL
,	NULL
by	NULL
inhibiting	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
perhaps	NULL
other	NULL
mechanisms	NULL
,	NULL
high	NULL
concentrations	NULL
of	NULL
salicylates	NULL
interfere	NULL
with	NULL
Th1-cell	NULL
differentiation	NULL
and	NULL
effector	NULL
responses	NULL
.	NULL
``	NULL

``	NULL
``	NULL
This	NULL
is	NULL
in	NULL
keeping	NULL
with	NULL
the	NULL
idea	NULL
that	NULL
NF-kB	NULL
activation	NULL
is	NULL
a	NULL
preferential	NULL
requirement	NULL
for	NULL
expression	NULL
of	NULL
cytokine	NULL
genes	NULL
in	NULL
Th1	NULL
cells	NULL
and	NULL
macrophages	NULL
.	NULL

``	NULL
8	NULL
``	NULL
``	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
ASA	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
effector	NULL
cytokines	NULL
in	NULL
purified	NULL
human	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
study	NULL
is	NULL
the	NULL
first	NULL
to	NULL
find	NULL
that	NULL
therapeutic	NULL
concentrations	NULL
of	NULL
ASA	NULL
can	NULL
significantly	NULL
and	NULL
selectively	NULL
inhibit	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
Th2-associated	NULL
cytokine	NULL
IL-4	NULL
.	NULL

This	NULL
effect	NULL
of	NULL
ASA	NULL
is	NULL
not	NULL
associated	NULL
with	NULL
reduced	NULL
cell	NULL
viability	NULL
or	NULL
detectable	NULL
apoptotic	NULL
changes	NULL
and	NULL
is	NULL
apparently	NULL
not	NULL
due	NULL
to	NULL
inhibition	NULL
or	NULL
acetylation	NULL
of	NULL
COX	NULL
isozymes	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
since	NULL
it	NULL
is	NULL
not	NULL
shared	NULL
with	NULL
other	NULL
NSAIDs	NULL
and	NULL
can	NULL
be	NULL
reproduced	NULL
in	NULL
experiments	NULL
using	NULL
identical	NULL
concentrations	NULL
of	NULL
the	NULL
nonacetylated	NULL
salicylate	NULL
SA	NULL
.	NULL

Our	NULL
findings	NULL
in	NULL
purified	NULL
CD4*	NULL
T	NULL
cells	NULL
provide	NULL
the	NULL
first	NULL
evidence	NULL
that	NULL
these	NULL
cells	NULL
may	NULL
be	NULL
a	NULL
direct	NULL
target	NULL
of	NULL
ASA	NULL
and	NULL
related	NULL
compounds	NULL
.	NULL

We	NULL
found	NULL
that	NULL
inhibition	NULL
of	NULL
IL-4	NULL
expression	NULL
by	NULL
ASA	NULL
and	NULL
SA	NULL
occurs	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
and	NULL
is	NULL
due	NULL
to	NULL
interference	NULL
with	NULL
the	NULL
binding	NULL
of	NULL
a	NULL
Ca	NULL
+*-inducible	NULL
factor	NULL
to	NULL
a	NULL
proximal	NULL
IL-4	NULL
promoter	NULL
element	NULL
.	NULL

Much	NULL
evidence	NULL
indicates	NULL
that	NULL
this	NULL
factor	NULL
is	NULL
not	NULL
NF-kB	NULL
and	NULL
points	NULL
to	NULL
a	NULL
previously	NULL
unrecognized	NULL
molecular	NULL
target	NULL
of	NULL
ASA	NULL
and	NULL
structurally	NULL
related	NULL
compounds	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cell	NULL
isolation	NULL
and	NULL
culture	NULL
Peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
PBT	NULL
)	NULL
were	NULL
enriched	NULL
by	NULL
elutriation	NULL
of	NULL
residual	NULL
cells	NULL
from	NULL
unidentified	NULL
healthy	NULL
donors	NULL
undergoing	NULL
hemapheresis	NULL
(	NULL
Oncology	NULL
Center	NULL
,	NULL
Johns	NULL
Hopkins	NULL
Medical	NULL
Institutions	NULL
,	NULL
Baltimore	NULL
,	NULL
MD	NULL
)	NULL
.	NULL
``	NULL

These	NULL
preparations	NULL
,	NULL
which	NULL
were	NULL
analyzed	NULL
for	NULL
expression	NULL
of	NULL
leukocyte	NULL
markers	NULL
with	NULL
an	NULL
Epics	NULL
Profile	NULL
II	NULL
cytometer	NULL
(	NULL
Beckman	NULL
Coulter	NULL
,	NULL
Fullerton	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
comprised	NULL
an	NULL
average	NULL
of	NULL
about	NULL
45	NULL
%	NULL
CD3*CD4*	NULL
cells	NULL
,	NULL
20	NULL
%	NULL
CD3*CD8*	NULL
,	NULL
5	NULL
%	NULL
CD19*	NULL
,	NULL
and	NULL
3	NULL
%	NULL
CD14*	NULL
.	NULL

CD3*CD4*	NULL
cells	NULL
were	NULL
purified	NULL
to	NULL
at	NULL
least	NULL
97	NULL
%	NULL
by	NULL
using	NULL
the	NULL
StemSep	NULL
CD4	NULL
*	NULL
T-cell	NULL
enrichment	NULL
cocktail	NULL
(	NULL
StemCell	NULL
Technologies	NULL
,	NULL
Vancouver	NULL
,	NULL
BC	NULL
)	NULL
and	NULL
magnetically	NULL
activated	NULL
cell-sorter	NULL
LS*	NULL
columns	NULL
(	NULL
Miltenyi	NULL
,	NULL
Auburn	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

PBT	NULL
and	NULL
the	NULL
Jurkat	NULL
human	NULL
T-cell	NULL
line	NULL
(	NULL
donated	NULL
by	NULL
Dr	NULL
Jack	NULL
L.	NULL
Strominger	NULL
,	NULL
Harvard	NULL
University	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
complete	NULL
medium	NULL
consisting	NULL
of	NULL
90	NULL
%	NULL
RPMI	NULL
1640	NULL
(	NULL
Biofluids	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Summit	NULL
,	NULL
Ft	NULL
Collins	NULL
,	NULL
CO	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
GlutaMax-I	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
and	NULL
40	NULL
ug/mL	NULL
gentamicin	NULL
.	NULL

Cell	NULL
stimulation	NULL
and	NULL
cytokine	NULL
detection	NULL
PBT	NULL
(	NULL
2	NULL
X	NULL
105/0.5	NULL
mL	NULL
)	NULL
were	NULL
stimulated	NULL
with	NULL
A23187	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
;	NULL
Calbiochem	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
or	NULL
murine	NULL
monoclonal	NULL
antibodies	NULL
against	NULL
human	NULL
CD3	NULL
(	NULL
clone	NULL
HIT3a	NULL
)	NULL
and	NULL
CD28	NULL
(	NULL
CD28.2	NULL
;	NULL
Pharmingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Enriched	NULL
PBT	NULL
(	NULL
2	NULL
X	NULL
105/mL	NULL
)	NULL
were	NULL
primed	NULL
by	NULL
6-day	NULL
incubation	NULL
in	NULL
complete	NULL
medium	NULL
containing	NULL
5	NULL
pg/mL	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
;	NULL
Calbiochem	NULL
)	NULL
with	NULL
or	NULL
without	NULL
50	NULL
ng/mL	NULL
IL-4	NULL
(	NULL
R	NULL
&	NULL
D	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
3	NULL
times	NULL
,	NULL
and	NULL
seeded	NULL
in	NULL
24-well	NULL
plates	NULL
(	NULL
10°/mL	NULL
)	NULL
for	NULL
restimulation	NULL
.	NULL

ASA	NULL
,	NULL
SA	NULL
,	NULL
indomethacin	NULL
(	NULL
IM	NULL
)	NULL
,	NULL
flurbiprofen	NULL
(	NULL
FBP	NULL
)	NULL
,	NULL
sulfasalazine	NULL
(	NULL
SSA	NULL
)	NULL
,	NULL
or	NULL
dimethyl	NULL
sulfoxide	NULL
(	NULL
DMSO	NULL
)	NULL
carrier	NULL
(	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
were	NULL
added	NULL
15	NULL
minutes	NULL
before	NULL
stimulation	NULL
.	NULL

Cytokine	NULL
titers	NULL
were	NULL
measured	NULL
in	NULL
supernatants	NULL
collected	NULL
18	NULL
to	NULL
20	NULL
hours	NULL
after	NULL
stimulation	NULL
by	NULL
using	NULL
Cytoscreen	NULL
human	NULL
IL-4	NULL
(	NULL
detection	NULL
limit	NULL
,	NULL
7.8	NULL
pg/mL	NULL
)	NULL
,	NULL
Cytoscreen	NULL
human	NULL
IFN-y	NULL
(	NULL
15.6	NULL
pg/mL	NULL
)	NULL
,	NULL
human	NULL
IL-2	NULL
(	NULL
1.1	NULL
U/mL	NULL
)	NULL
enzyme-amplified	NULL
sensitivity	NULL
immunoassay	NULL
(	NULL
BioSource	NULL
,	NULL
Camarillo	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
and	NULL
IL-13	NULL
(	NULL
7.8	NULL
pg/mL	NULL
)	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
kits	NULL
(	NULL
Immuno-tech	NULL
,	NULL
Marseille	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
assessed	NULL
by	NULL
using	NULL
trypan	NULL
blue	NULL
or	NULL
INHIBITION	NULL
OF	NULL
T-CELL	NULL
IL-4	NULL
EXPRESSION	NULL
BY	NULL
ASPIRIN	NULL
_	NULL
1743	NULL
propidium	NULL
iodide	NULL
exclusion	NULL
.	NULL

In	NULL
selected	NULL
experiments	NULL
,	NULL
cells	NULL
treated	NULL
with	NULL
ASA	NULL
,	NULL
SA	NULL
,	NULL
or	NULL
mouse	NULL
antihuman	NULL
CD95	NULL
(	NULL
BioSource	NULL
)	NULL
were	NULL
analyzed	NULL
for	NULL
expression	NULL
of	NULL
early	NULL
apoptotic	NULL
markers	NULL
by	NULL
staining	NULL
with	NULL
annexin	NULL
V-fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
;	NULL
ApoAlert	NULL
;	NULL
ClonTech	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

RNA	NULL
isolation	NULL
and	NULL
analysis	NULL
The	NULL
expression	NULL
of	NULL
cytokine	NULL
transcripts	NULL
was	NULL
analyzed	NULL
by	NULL
reverse	NULL
transcriptase	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
RT-PCR	NULL
)	NULL
of	NULL
total	NULL
RNA	NULL
extracted	NULL
6	NULL
hours	NULL
after	NULL
stimulation	NULL
with	NULL
the	NULL
Trizol	NULL
reagent	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
.	NULL
``	NULL

The	NULL
primers	NULL
used	NULL
were	NULL
(	NULL
forward	NULL
IL-4	NULL
)	NULL
,	NULL
5'-TGCTT-GTGCCTGTGGAACTGC-3	NULL
'	NULL
(	NULL
reverse	NULL
IL-4	NULL
)	NULL
,	NULL
5-AAGGCTCCGCTCTG-CAATGG-3	NULL
'	NULL
(	NULL
forward	NULL
IL-13	NULL
)	NULL
,	NULL
5-GGGCCACCTCGATTTTGGTGT-3	NULL
'	NULL
(	NULL
reverse	NULL
IL-13	NULL
)	NULL
,	NULL
5-GCATCCAAAAGAGTGTGGAGACCATC-3	NULL
'	NULL
(	NULL
forward	NULL
IFN-y	NULL
)	NULL
,	NULL
5'-CGACCTCGAAACAGCATCTGACT-3	NULL
'	NULL
(	NULL
reverse	NULL
IFN-y	NULL
)	NULL
,	NULL
5	NULL
``	NULL
-CATGCCCAAGAAGGCCACAGA-3	NULL
'	NULL
(	NULL
forward	NULL
IL-2	NULL
)	NULL
,	NULL
and	NULL
CATCAGCATATTCACACATGA-3	NULL
'	NULL
(	NULL
reverse	NULL
IL-2	NULL
)	NULL
(	NULL
all	NULL
from	NULL
Genosys	NULL
,	NULL
The	NULL
Woodlands	NULL
,	NULL
TX	NULL
)	NULL
.	NULL

Primers	NULL
for	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
were	NULL
from	NULL
Stratagene	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

IL-4	NULL
transcripts	NULL
were	NULL
quantified	NULL
by	NULL
real-time	NULL
RT-PCR	NULL
.	NULL
``	NULL

Total	NULL
RNA	NULL
(	NULL
10	NULL
ng/sample	NULL
)	NULL
was	NULL
subjected	NULL
to	NULL
RT-PCR	NULL
using	NULL
the	NULL
GeneAmp	NULL
Gold	NULL
kit	NULL
(	NULL
Applied	NULL
Biosystems	NULL
,	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Quantitative	NULL
determination	NULL
of	NULL
the	NULL
amplified	NULL
products	NULL
was	NULL
done	NULL
with	NULL
an	NULL
ABI	NULL
Prism	NULL
7700	NULL
System	NULL
(	NULL
Applied	NULL
Biosystems	NULL
)	NULL
.	NULL

The	NULL
forward	NULL
and	NULL
reverse	NULL
primers	NULL
were	NULL
5	NULL
-CGACTGCACAGCAGTTCCA-3	NULL
``	NULL
'	NULL
and	NULL
5-CAGGCCCCAGAGGT-TCC-3	NULL
'	NULL
,	NULL
respectively	NULL
(	NULL
Applied	NULL
Biosystems	NULL
)	NULL
.	NULL

The	NULL
detection	NULL
probe	NULL
,	NULL
labeled	NULL
with	NULL
the	NULL
reporter	NULL
dye	NULL
6-carboxy-fluorescein	NULL
(	NULL
Apx	NULL
,	NULL
518	NULL
nm	NULL
)	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
and	NULL
the	NULL
quencher	NULL
dye	NULL
6-carboxytetramethyl-rhodamine	NULL
(	NULL
A	NULL
;	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
582	NULL
nm	NULL
)	NULL
at	NULL
the	NULL
3	NULL
``	NULL
end	NULL
,	NULL
was	NULL
5-TCCGATTCCTGAAACGGCTCGACA-3	NULL
'	NULL
(	NULL
Applied	NULL
Biosystems	NULL
)	NULL
.	NULL

GAPDH	NULL
was	NULL
monitored	NULL
by	NULL
using	NULL
reagents	NULL
from	NULL
Applied	NULL
Biosystems	NULL
.	NULL

Cycle	NULL
threshold	NULL
(	NULL
C	NULL
;	NULL
)	NULL
values	NULL
were	NULL
calculated	NULL
for	NULL
IL-4	NULL
and	NULL
GAPDH	NULL
.	NULL

The	NULL
relative	NULL
IL-4	NULL
transcript	NULL
levels	NULL
in	NULL
treated	NULL
(	NULL
T	NULL
)	NULL
and	NULL
control	NULL
(	NULL
C	NULL
)	NULL
samples	NULL
were	NULL
expressed	NULL
as	NULL
2-AAC	NULL
;	NULL
,	NULL
in	NULL
which	NULL
AACr	NULL
=	NULL
ACrmy	NULL
-	NULL
AGrg	NULL
,	NULL
and	NULL
AC	NULL
;	NULL
=	NULL
Crary	NULL
-	NULL
for	NULL
each	NULL
experimental	NULL
condition	NULL
.	NULL

Transient	NULL
transfections	NULL
and	NULL
analysis	NULL
of	NULL
reporter	NULL
gene	NULL
expression	NULL
The	NULL
1L-4.265	NULL
,	NULL
IL-4.225	NULL
,	NULL
IL-4.145	NULL
,	NULL
IL-4.95	NULL
,	NULL
and	NULL
IL-4.65	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
plasmids	NULL
were	NULL
constructed	NULL
by	NULL
insertion	NULL
in	NULL
the	NULL
HindIII	NULL
and	NULL
Xbal	NULL
sites	NULL
of	NULL
pCAT-Basic	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
of	NULL
PCR-generated	NULL
fragments	NULL
spanning	NULL
base	NULL
pairs	NULL
(	NULL
bp	NULL
)	NULL
-265	NULL
,	NULL
-225	NULL
,	NULL
-145	NULL
,	NULL
-95	NULL
,	NULL
and	NULL
-65	NULL
,	NULL
respectively	NULL
,	NULL
to	NULL
+55	NULL
of	NULL
the	NULL
human	NULL
IL-4	NULL
gene	NULL
.	NULL

``	NULL
*	NULL
``	NULL
The	NULL
IL-2.15ACX	NULL
CAT	NULL
plasmid	NULL
(	NULL
IL-2.312	NULL
)	NULL
,	NULL
including	NULL
bp	NULL
-312	NULL
to	NULL
+55	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
gene	NULL
,	NULL
was	NULL
donated	NULL
by	NULL
Dr	NULL
Gerald	NULL
R.	NULL
Crabtree	NULL
(	NULL
Stanford	NULL
University	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

``	NULL
*	NULL
Plasmids	NULL
(	NULL
1	NULL
pg	NULL
)	NULL
were	NULL
transfected	NULL
into	NULL
10°	NULL
Jurkat	NULL
cells	NULL
by	NULL
48-hour	NULL
incubation	NULL
in	NULL
3	NULL
mL	NULL
complete	NULL
medium	NULL
containing	NULL
5	NULL
g/mL	NULL
SuperFect	NULL
(	NULL
Qiagen	NULL
,	NULL
Valencia	NULL
,	NULL
CA	NULL
)	NULL
.	NULL
``	NULL

Cells	NULL
were	NULL
treated	NULL
as	NULL
indicated	NULL
20	NULL
hours	NULL
before	NULL
harvest	NULL
.	NULL

Expression	NULL
of	NULL
CAT	NULL
was	NULL
measured	NULL
by	NULL
using	NULL
a	NULL
commercial	NULL
ELISA	NULL
(	NULL
Roche	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
and	NULL
normalized	NULL
by	NULL
considering	NULL
the	NULL
total	NULL
protein	NULL
in	NULL
each	NULL
sample	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Hercules	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
Jurkat	NULL
cells	NULL
(	NULL
2.5	NULL
X	NULL
10	NULL
``	NULL
'/condition	NULL
)	NULL
were	NULL
lysed	NULL
in	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
30	NULL
mM	NULL
potassium	NULL
chloride	NULL
(	NULL
KC	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
,	NULL
0.5	NULL
g/mL	NULL
leupeptin	NULL
,	NULL
1	NULL
jug/mL	NULL
aprotinin	NULL
,	NULL
and	NULL
0.075	NULL
%	NULL
Nonidet	NULL
P40	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Nuclei	NULL
were	NULL
extracted	NULL
in	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
420	NULL
mM	NULL
KC	NULL
]	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
PMSE	NULL
,	NULL
0.5	NULL
pg/mL	NULL
leupeptin	NULL
,	NULL
1	NULL
g/mL	NULL
aprotinin	NULL
,	NULL
and	NULL
20	NULL
%	NULL
glycerol	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
measured	NULL
by	NULL
using	NULL
the	NULL
Bradford	NULL
reagent	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

The	NULL
following	NULL
oligonucleotides	NULL
spanning	NULL
IL-4	NULL
promoter	NULL
elements	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
were	NULL
synthesized	NULL
(	NULL
Genosys	NULL
)	NULL
:	NULL
5'-TTACCTGTTTGTGAGGCATTTTITC-3	NULL
'	NULL
(	NULL
IL4.155	NULL
)	NULL
,	NULL
5	NULL
``	NULL
-TTITTCTCCTG-GAAGAGAGGTGCTGA-3	NULL
'	NULL
(	NULL
IL-4.135	NULL
)	NULL
,	NULL
5*-TTTTCTCCTGGAAGAGAGGT-GCTGA-3	NULL
'	NULL
(	NULL
IL-4.115	NULL
)	NULL
,	NULL
and	NULL
5-GAGAGGTGCTGATTGGCCCCAAGT3	NULL
'	NULL
(	NULL
IL4.CCAAT	NULL
)	NULL
.	NULL

These	NULL
oligonucleotides	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
22	NULL
mer	NULL
spanning	NULL
a	NULL
consensus	NULL
NF-	NULL
«	NULL
B	NULL
element	NULL
from	NULL
the	NULL
mouse	NULL
immunoglobulin	NULL
x	NULL
light-chain	NULL
gene	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
were	NULL
labeled	NULL
by	NULL
random	NULL
hexamer	NULL
priming	NULL
using	NULL
-phosphorus	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1744	NULL
__	NULL
CIANFERON	NULL
!	NULL

etal	NULL
32-deoxycytidine	NULL
triphosphate	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Then	NULL
,	NULL
5	NULL
to	NULL
20	NULL
fmol	NULL
of	NULL
the	NULL
probe	NULL
(	NULL
10	NULL
000-30	NULL
000	NULL
cpm	NULL
)	NULL
was	NULL
incubated	NULL
(	NULL
30	NULL
minutes	NULL
,	NULL
25°C	NULL
)	NULL
with	NULL
5	NULL
ug	NULL
nuclear	NULL
extracts	NULL
in	NULL
12	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
50	NULL
rmiM	NULL
KCI	NULL
,	NULL
0.5	NULL
mM	NULL
magnesium	NULL
chloride	NULL
,	NULL
0.24	NULL
mM	NULL
EDTA	NULL
,	NULL
4	NULL
mM	NULL
DTT	NULL
,	NULL
12	NULL
%	NULL
glycerol	NULL
,	NULL
0.1	NULL
mg/mL	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
and	NULL
30	NULL
g/mL	NULL
poly	NULL
(	NULL
dI	NULL
»	NULL
dC	NULL
)	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
)	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
the	NULL
binding	NULL
reactions	NULL
were	NULL
incubated	NULL
(	NULL
30	NULL
minutes	NULL
,	NULL
4°C	NULL
)	NULL
with	NULL
rabbit	NULL
antiserum	NULL
for	NULL
NF	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
1	NULL
(	NULL
Upstate	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
CCAAT-binding	NULL
factor	NULL
(	NULL
CBF	NULL
)	NULL
A	NULL
(	NULL
Accurate	NULL
,	NULL
Westbury	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
Ets-1	NULL
and	NULL
Ets-2	NULL
,	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
and	NULL
p50	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
resolved	NULL
by	NULL
4	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
in	NULL
45	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8.2	NULL
)	NULL
,	NULL
45	NULL
mM	NULL
boric	NULL
acid	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
and	NULL
then	NULL
visualized	NULL
by	NULL
using	NULL
autoradiography	NULL
.	NULL

Results	NULL
Aspirin	NULL
selectively	NULL
inhibits	NULL
IL-4	NULL
secretion	NULL
from	NULL
CD4+	NULL
T	NULL
cells	NULL
We	NULL
studied	NULL
the	NULL
effects	NULL
of	NULL
ASA	NULL
on	NULL
the	NULL
secretion	NULL
of	NULL
effector	NULL
cytokines	NULL
from	NULL
freshly	NULL
isolated	NULL
CD4*	NULL
PBT	NULL
.	NULL

Suppression	NULL
of	NULL
PG	NULL
production	NULL
in	NULL
monocytes	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
reported	NULL
enhancing	NULL
effects	NULL
of	NULL
NSAIDs	NULL
,	NULL
including	NULL
ASA	NULL
,	NULL
on	NULL
T-cell	NULL
proliferation	NULL
and	NULL
IFN-y	NULL
and	NULL
IL-2	NULL
expression	NULL
.	NULL
``	NULL

Although	NULL
both	NULL
COX-1	NULL
and	NULL
COX-2	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
expressed	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
importance	NULL
of	NULL
this	NULL
finding	NULL
is	NULL
not	NULL
clear	NULL
.	NULL
``	NULL

To	NULL
minimize	NULL
the	NULL
contribution	NULL
of	NULL
monocytes	NULL
or	NULL
other	NULL
accessory	NULL
cells	NULL
to	NULL
the	NULL
possible	NULL
effects	NULL
of	NULL
ASA	NULL
on	NULL
T-cell	NULL
activation	NULL
,	NULL
we	NULL
purified	NULL
CD3*CD4*	NULL
cells	NULL
to	NULL
at	NULL
least	NULL
97	NULL
%	NULL
by	NULL
means	NULL
of	NULL
negative	NULL
selection	NULL
from	NULL
enriched	NULL
PBT	NULL
preparations	NULL
.	NULL

CD4+*	NULL
PBT	NULL
were	NULL
treated	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
ASA	NULL
(	NULL
10-5-3	NULL
X	NULL
M	NULL
)	NULL
15	NULL
minutes	NULL
before	NULL
stimulation	NULL
with	NULL
the	NULL
Ca++	NULL
ionophore	NULL
A23187	NULL
(	NULL
0.5	NULL
pg/mL	NULL
)	NULL
and	NULL
the	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
agonist	NULL
PMA	NULL
(	NULL
25	NULL
ng/mL	NULL
)	NULL
.	NULL

These	NULL
concentrations	NULL
of	NULL
ASA	NULL
were	NULL
chosen	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
plasma	NULL
levels	NULL
known	NULL
to	NULL
be	NULL
therapeutic	NULL
in	NULL
patients	NULL
with	NULL
chronic	NULL
inflammatory	NULL
conditions	NULL
.	NULL
``	NULL

''	NULL
Figure	NULL
1A	NULL
shows	NULL
the	NULL
effect	NULL
of	NULL
10~	NULL
``	NULL
M	NULL
ASA	NULL
on	NULL
IL-4	NULL
,	NULL
IL-13	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
IL-2	NULL
secretion	NULL
in	NULL
these	NULL
experiments	NULL
.	NULL

ASA	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
production	NULL
of	NULL
IL-13	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
IL-2	NULL
,	NULL
but	NULL
it	NULL
significantly	NULL
inhibited	NULL
IL-4	NULL
secretion	NULL
(	NULL
by	NULL
47	NULL
%	NULL
+	NULL
2.4	NULL
%	NULL
in	NULL
3	NULL
experiments	NULL
;	NULL
P	NULL
<	NULL
.05	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
1B	NULL
,	NULL
10-3	NULL
M	NULL
ASA	NULL
was	NULL
the	NULL
lowest	NULL
concentration	NULL
that	NULL
significantly	NULL
inhibited	NULL
IL-4	NULL
expression	NULL
in	NULL
these	NULL
cultures	NULL
,	NULL
whereas	NULL
none	NULL
of	NULL
the	NULL
concentrations	NULL
tested	NULL
affected	NULL
IL-2	NULL
secretion	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
enriched	NULL
preparations	NULL
containing	NULL
about	NULL
45	NULL
%	NULL
CD4+*	NULL
PBT	NULL
and	NULL
substantial	NULL
percentages	NULL
of	NULL
accessory	NULL
cells	NULL
.	NULL

Figure	NULL
1C	NULL
shows	NULL
the	NULL
effect	NULL
of	NULL
10~	NULL
'	NULL
M	NULL
ASA	NULL
on	NULL
IL-4	NULL
expression	NULL
in	NULL
these	NULL
preparations	NULL
,	NULL
stimulated	NULL
with	NULL
either	NULL
A23187	NULL
(	NULL
0.25	NULL
g/mL	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
25	NULL
ng/mL	NULL
)	NULL
or	NULL
with	NULL
anti-CD3	NULL
(	NULL
3	NULL
pg/mL	NULL
)	NULL
and	NULL
anti-CD28	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
5	NULL
ug/mL	NULL
)	NULL
.	NULL

A	NULL
short	NULL
incubation	NULL
(	NULL
15	NULL
minutes	NULL
)	NULL
with	NULL
this	NULL
concentration	NULL
of	NULL
ASA	NULL
consistently	NULL
and	NULL
significantly	NULL
inhibited	NULL
IL-4	NULL
secretion	NULL
,	NULL
irrespective	NULL
of	NULL
the	NULL
stimulants	NULL
used	NULL
.	NULL

Although	NULL
ASA	NULL
did	NULL
not	NULL
affect	NULL
IL-2	NULL
secretion	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
A23187	NULL
and	NULL
PMA	NULL
,	NULL
it	NULL
enhanced	NULL
expression	NULL
of	NULL
this	NULL
cytokine	NULL
induced	NULL
by	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
or	NULL
by	NULL
A23187	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Figure	NULL
1D	NULL
shows	NULL
that	NULL
10~	NULL
'	NULL
M	NULL
ASA	NULL
inhibited	NULL
to	NULL
a	NULL
comparable	NULL
degree	NULL
IL-4	NULL
expression	NULL
in	NULL
mitogen-primed	NULL
enriched	NULL
PBT	NULL
stimulated	NULL
with	NULL
A23187	NULL
and	NULL
PMA	NULL
.	NULL

Although	NULL
expression	NULL
of	NULL
IL-4	NULL
was	NULL
at	NULL
a	NULL
lower	NULL
level	NULL
in	NULL
these	NULL
cultures	NULL
than	NULL
in	NULL
freshly	NULL
isolated	NULL
PBT	NULL
,	NULL
presumably	NULL
because	NULL
of	NULL
the	NULL
antagonizing	NULL
effects	NULL
of	NULL
Th1-associated	NULL
cytokines	NULL
,	NULL
``	NULL
``	NULL
ASA	NULL
was	NULL
at	NULL
least	NULL
as	NULL
effective	NULL
at	NULL
inhibiting	NULL
IL-4	NULL
production	NULL
in	NULL
cells	NULL
cultured	NULL
under	NULL
Th2-biasing	NULL
conditions	NULL
,	NULL
such	NULL
as	NULL
inclusion	NULL
of	NULL
IL-4	NULL
(	NULL
50	NULL
ng/mL	NULL
)	NULL
in	NULL
the	NULL
priming	NULL
medium	NULL
(	NULL
Figure	NULL
1D	NULL
)	NULL
.	NULL
``	NULL

''	NULL
However	NULL
,	NULL
the	NULL
baseline	NULL
cytokine	NULL
profiles-in	NULL
particular	NULL
,	NULL
the	NULL
frequencies	NULL
of	NULL
IL-4-expressing	NULL
cells	NULL
compared	NULL
with	NULL
BLOOD	NULL
,	NULL
15	NULL
MARCH	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
6	NULL
1200	NULL
*	NULL
*	NULL
+a0o	NULL
e	NULL
|	NULL
|r	NULL
00	NULL
|	NULL
4	NULL
;	NULL
eCD3+aCD28	NULL
.	NULL

AZM187+PMA	NULL
Figure	NULL
1	NULL
.	NULL

Selective	NULL
inhibition	NULL
of	NULL
IL-4	NULL
secretion	NULL
in	NULL
CD4+	NULL
PBT	NULL
treated	NULL
with	NULL
ASA	NULL
.	NULL

(	NULL
A	NULL
)	NULL
IL-4	NULL
,	NULL
IL-13	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
IL-2	NULL
secretion	NULL
in	NULL
PBT	NULL
(	NULL
purified	NULL
to	NULL
>	NULL
97	NULL
%	NULL
CD3*CD4*	NULL
)	NULL
treated	NULL
with	NULL
a	NULL
therapeutic	NULL
concentration	NULL
of	NULL
ASA	NULL
(	NULL
10~°	NULL
M	NULL
)	NULL
or	NULL
the	NULL
corresponding	NULL
amount	NULL
of	NULL
DMSO	NULL
carrier	NULL
(	NULL
0.1	NULL
%	NULL
)	NULL
15	NULL
minutes	NULL
before	NULL
20-hour	NULL
stimulation	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
mg/ml	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
25	NULL
ng/mL	NULL
)	NULL
.	NULL

Shown	NULL
is	NULL
the	NULL
mean	NULL
+	NULL
SEM	NULL
percentage	NULL
of	NULL
IL-4	NULL
(	NULL
615.7	NULL
+	NULL
70.5	NULL
pg/mL	NULL
)	NULL
,	NULL
IL-13	NULL
(	NULL
253.2	NULL
+	NULL
110.5	NULL
pg/mL	NULL
)	NULL
,	NULL
IFN-y	NULL
(	NULL
1.1	NULL
+	NULL
0.1	NULL
ng/mL	NULL
)	NULL
,	NULL
and	NULL
IL-2	NULL
(	NULL
158.2	NULL
+	NULL
67.5	NULL
U/mL	NULL
)	NULL
secretion	NULL
from	NULL
DMSO-treated	NULL
controls	NULL
in	NULL
3	NULL
independent	NULL
experiments	NULL
done	NULL
in	NULL
duplicate	NULL
.	NULL

The	NULL
asterisk	NULL
indicates	NULL
P	NULL
<	NULL
.05	NULL
(	NULL
Wilcoxon	NULL
test	NULL
)	NULL
relative	NULL
to	NULL
controls	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Purified	NULL
PBT	NULL
(	NULL
>	NULL
97	NULL
%	NULL
CD3*CD4*	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
ASA	NULL
(	NULL
104-3	NULL
x	NULL
10~*	NULL
M	NULL
)	NULL
or	NULL
corresponding	NULL
amounts	NULL
of	NULL
DMSO	NULL
before	NULL
stimulation	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
pg/mL	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
25	NULL
ng/mL	NULL
)	NULL
.	NULL

The	NULL
mean	NULL
+	NULL
SEM	NULL
percentage	NULL
of	NULL
control	NULL
IL-4	NULL
(	NULL
@	NULL
,	NULL
595.1	NULL
+	NULL
28.9	NULL
pg/mL	NULL
)	NULL
and	NULL
IL-2	NULL
(	NULL
0	NULL
,	NULL
364.4	NULL
+	NULL
39.7	NULL
U/mL	NULL
)	NULL
secretion	NULL
in	NULL
4	NULL
independent	NULL
experiments	NULL
done	NULL
in	NULL
duplicate	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
asterisk	NULL
indicates	NULL
P	NULL
<	NULL
.05	NULL
(	NULL
Wilcoxon	NULL
test	NULL
)	NULL
relative	NULL
to	NULL
DMSO-treated	NULL
controls	NULL
.	NULL

(	NULL
C	NULL
)	NULL
IL-4	NULL
concentrations	NULL
in	NULL
the	NULL
supernatants	NULL
of	NULL
enriched	NULL
PBT	NULL
preparations	NULL
(	NULL
33	NULL
%	NULL
-54	NULL
%	NULL
CD3+CD4	NULL
#	NULL
+	NULL
)	NULL
treated	NULL
with	NULL
10-	NULL
``	NULL
M	NULL
ASA	NULL
(	NULL
BMI	NULL
)	NULL
or	NULL
0.1	NULL
%	NULL
DMSO	NULL
(	NULL
C	NULL
]	NULL
)	NULL
before	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
(	NULL
[	NULL
eCD3	NULL
]	NULL
;	NULL
3	NULL
ug/ml	NULL
)	NULL
and	NULL
anti-CD28	NULL
(	NULL
[	NULL
«	NULL
CD28	NULL
]	NULL
;	NULL
5	NULL
ug/ml	NULL
)	NULL
monoclonal	NULL
antibodies	NULL
or	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
mg/ml	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
25	NULL
ng/mL	NULL
)	NULL
.	NULL

The	NULL
mean	NULL
+	NULL
SEM	NULL
result	NULL
from	NULL
3	NULL
independent	NULL
experiments	NULL
done	NULL
in	NULL
duplicate	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
asterisk	NULL
indicates	NULL
P	NULL
<	NULL
.05	NULL
(	NULL
Wilcoxon	NULL
test	NULL
)	NULL
relative	NULL
to	NULL
DMSO-treated	NULL
controls	NULL
.	NULL

(	NULL
D	NULL
)	NULL
IL-4	NULL
concentrations	NULL
in	NULL
the	NULL
supernatants	NULL
of	NULL
enriched	NULL
PBT	NULL
primed	NULL
with	NULL
PHA	NULL
(	NULL
5	NULL
g/mL	NULL
;	NULL
control	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
IL-4	NULL
(	NULL
50	NULL
ng/mL	NULL
)	NULL
,	NULL
then	NULL
treated	NULL
with	NULL
ASA	NULL
(	NULL
ill	NULL
,	NULL
10~°	NULL
M	NULL
)	NULL
or	NULL
DMSO	NULL
(	NULL
C	NULL
,	NULL
0.1	NULL
%	NULL
)	NULL
15	NULL
minutes	NULL
before	NULL
restimulation	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
g/mL	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
25	NULL
ng/mL	NULL
)	NULL
.	NULL

The	NULL
mean	NULL
+	NULL
SEM	NULL
result	NULL
from	NULL
3	NULL
independent	NULL
experiments	NULL
done	NULL
in	NULL
duplicate	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
asterisk	NULL
indicates	NULL
P	NULL
<	NULL
.05	NULL
(	NULL
Wilcoxon	NULL
test	NULL
)	NULL
relative	NULL
to	NULL
DMSO-treated	NULL
controls	NULL
.	NULL

3	NULL
5	NULL
i	NULL
4	NULL
Percent	NULL
of	NULL
control	NULL
QJ	NULL
.+	NULL
‘	NULL
~~	NULL
L	NULL
Fa	NULL
ri	NULL
I	NULL
rth	NULL
+	NULL
Percent	NULL
of	NULL
control	NULL
--	NULL
|_	NULL
|	NULL
10+	NULL
10°	NULL
ASA	NULL
(	NULL
moWL	NULL
)	NULL
o	NULL
8	NULL
S	NULL
[	NULL
w	NULL
]	NULL
8	NULL
IL-4	NULL
(	NULL
pg/mL	NULL
)	NULL
8	NULL
IL-4	NULL
(	NULL
pg/mL	NULL
)	NULL
&	NULL
&	NULL
i	NULL
5	NULL
o	NULL
o	NULL
Control	NULL
L4	NULL
IFN-y-expressing	NULL
cells-were	NULL
not	NULL
significantly	NULL
affected	NULL
in	NULL
PBT	NULL
primed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10-	NULL
``	NULL
M	NULL
ASA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

COX	NULL
inhibition	NULL
and	NULL
acetylation	NULL
play	NULL
no	NULL
role	NULL
in	NULL
IL-4	NULL
inhibition	NULL
by	NULL
aspirin	NULL
To	NULL
assess	NULL
whether	NULL
inhibition	NULL
of	NULL
PG	NULL
generation	NULL
might	NULL
account	NULL
for	NULL
IL-4	NULL
inhibition	NULL
by	NULL
ASA	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
effects	NULL
of	NULL
different	NULL
COX	NULL
inhibitors	NULL
on	NULL
expression	NULL
of	NULL
this	NULL
cytokine	NULL
in	NULL
purified	NULL
CD4*	NULL
PBT	NULL
.	NULL

Figure	NULL
2	NULL
shows	NULL
that	NULL
among	NULL
several	NULL
NSAIDs	NULL
,	NULL
only	NULL
SA	NULL
,	NULL
the	NULL
weakest	NULL
inhibitor	NULL
of	NULL
COX-1	NULL
and	NULL
COX-2	NULL
in	NULL
this	NULL
pharmacologic	NULL
group	NULL
,	NULL
``	NULL
inhibited	NULL
IL-4	NULL
expression	NULL
to	NULL
an	NULL
extent	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
ASA	NULL
.	NULL

In	NULL
striking	NULL
contrast	NULL
to	NULL
this	NULL
finding	NULL
,	NULL
the	NULL
potent	NULL
COX	NULL
inhibitors	NULL
FBP	NULL
and	NULL
IM	NULL
,	NULL
used	NULL
at	NULL
concentrations	NULL
in	NULL
or	NULL
above	NULL
their	NULL
respective	NULL
COX-inhibitory	NULL
and	NULL
therapeutic	NULL
ranges	NULL
,	NULL
``	NULL
did	NULL
not	NULL
affect	NULL
IL-4	NULL
expression	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

Neither	NULL
of	NULL
these	NULL
compounds	NULL
significantly	NULL
affected	NULL
IL-2	NULL
secretion	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
,	NULL
ASA	NULL
or	NULL
other	NULL
NSAIDs	NULL
did	NULL
not	NULL
affect	NULL
cell	NULL
viability	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
trypan	NULL
blue	NULL
or	NULL
propidium	NULL
iodide	NULL
exclusion	NULL
.	NULL

Even	NULL
longer	NULL
incubations	NULL
(	NULL
up	NULL
to	NULL
72	NULL
hours	NULL
)	NULL
of	NULL
enriched	NULL
or	NULL
purified	NULL
CD4+*	NULL
PBT	NULL
with	NULL
10-3	NULL
M	NULL
ASA	NULL
or	NULL
SA	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
proliferative	NULL
responses	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
nonspecific	NULL
mitogens	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
verify	NULL
whether	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
ASA	NULL
and	NULL
SA	NULL
on	NULL
IL-4	NULL
expression	NULL
were	NULL
associated	NULL
with	NULL
induction	NULL
of	NULL
apoptotic	NULL
changes	NULL
in	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
15	NULL
MARCH	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
6	NULL
120	NULL
6	NULL
£	NULL
1004	NULL
5	NULL
G	NULL
so	NULL
5	NULL
60	NULL
*	NULL
‘	NULL
E	NULL
*	NULL
6	NULL
$	NULL
401	NULL
G	NULL
Q	NULL
20A	NULL
0	NULL
ASA	NULL
SA	NULL
IM	NULL
FBP	NULL
Figure	NULL
2	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
different	NULL
NSAIDs	NULL
on	NULL
IL-2	NULL
and	NULL
IL-4	NULL
secretion	NULL
from	NULL
CD4+	NULL
PBT	NULL
.	NULL

Purified	NULL
PBT	NULL
(	NULL
>	NULL
97	NULL
%	NULL
CD3+*CD4*	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
optimal	NULL
concentrations	NULL
of	NULL
ASA	NULL
M	NULL
)	NULL
,	NULL
SA	NULL
(	NULL
10~*	NULL
M	NULL
}	NULL
,	NULL
IM	NULL
(	NULL
10-5	NULL
M	NULL
)	NULL
,	NULL
and	NULL
FBP	NULL
(	NULL
10-5	NULL
M	NULL
)	NULL
or	NULL
corresponding	NULL
amounts	NULL
of	NULL
DMSO	NULL
carrier	NULL
(	NULL
up	NULL
to	NULL
0.1	NULL
%	NULL
)	NULL
before	NULL
stimulation	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
and	NULL
A23187	NULL
(	NULL
0.5	NULL
mg/mL	NULL
)	NULL
.	NULL

The	NULL
mean	NULL
+	NULL
SEM	NULL
percentage	NULL
of	NULL
control	NULL
IL-4	NULL
(	NULL
M	NULL
,	NULL
572.4	NULL
+	NULL
26.2	NULL
pg/mL	NULL
)	NULL
and	NULL
IL-2	NULL
(	NULL
C	NULL
]	NULL
,	NULL
194.8	NULL
+	NULL
43.4	NULL
U/mL	NULL
)	NULL
secretion	NULL
in	NULL
4	NULL
independent	NULL
experiments	NULL
done	NULL
in	NULL
duplicate	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
asterisk	NULL
indicates	NULL
P	NULL
<	NULL
.05	NULL
(	NULL
Wilcoxon	NULL
test	NULL
)	NULL
relative	NULL
to	NULL
DMSO-treated	NULL
controls	NULL
.	NULL

PBT	NULL
,	NULL
we	NULL
conducted	NULL
parallel	NULL
experiments	NULL
to	NULL
analyze	NULL
the	NULL
binding	NULL
of	NULL
FITC-labeled	NULL
annexin	NULL
V	NULL
after	NULL
treatment	NULL
with	NULL
increasing	NULL
concentrations	NULL
(	NULL
1074-3	NULL
X	NULL
10-	NULL
M	NULL
)	NULL
of	NULL
the	NULL
2	NULL
salicylates	NULL
and	NULL
stimulation	NULL
with	NULL
A23187	NULL
and	NULL
PMA	NULL
.	NULL

``	NULL
°	NULL
A	NULL
20-hour	NULL
incubation	NULL
with	NULL
3	NULL
X	NULL
10-3	NULL
M	NULL
ASA	NULL
produced	NULL
6	NULL
%	NULL
annexin	NULL
V-binding	NULL
cells	NULL
,	NULL
a	NULL
frequency	NULL
that	NULL
did	NULL
not	NULL
differ	NULL
substantially	NULL
from	NULL
that	NULL
in	NULL
DMSO-treated	NULL
control	NULL
samples	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
experiments	NULL
using	NULL
SA	NULL
,	NULL
IM	NULL
,	NULL
or	NULL
FBP	NULL
,	NULL
whereas	NULL
up	NULL
to	NULL
11.9	NULL
%	NULL
of	NULL
cells	NULL
were	NULL
stained	NULL
by	NULL
annexin	NULL
V	NULL
after	NULL
similar	NULL
incubation	NULL
with	NULL
anti-€CD95	NULL
antibodies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Aspirin	NULL
inhibits	NULL
IL-4	NULL
gene	NULL
expression	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
Decreased	NULL
IL-4	NULL
secretion	NULL
was	NULL
paralleled	NULL
by	NULL
reduced	NULL
accumulation	NULL
of	NULL
IL-4	NULL
message	NULL
in	NULL
CD4+*	NULL
PBT	NULL
treated	NULL
with	NULL
ASA	NULL
.	NULL

Figure	NULL
3A	NULL
shows	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
10-	NULL
``	NULL
M	NULL
ASA	NULL
on	NULL
IL-4	NULL
RNA	NULL
expression	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
0.5	NULL
g/mL	NULL
A23187	NULL
and	NULL
10	NULL
ng/mL	NULL
PMA	NULL
.	NULL

Also	NULL
shown	NULL
is	NULL
that	NULL
this	NULL
concentration	NULL
of	NULL
ASA	NULL
did	NULL
not	NULL
affect	NULL
IL-13	NULL
,	NULL
IFN-y	NULL
,	NULL
or	NULL
IL-2	NULL
expression	NULL
in	NULL
these	NULL
experiments	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
IL-4	NULL
RNA	NULL
inhibition	NULL
by	NULL
ASA	NULL
was	NULL
analyzed	NULL
by	NULL
using	NULL
real-time	NULL
quantitative	NULL
RT-PCR	NULL
.	NULL

In	NULL
3	NULL
such	NULL
experiments	NULL
,	NULL
IL-4	NULL
RNA	NULL
levels	NULL
were	NULL
decreased	NULL
by	NULL
56.4	NULL
%	NULL
+	NULL
7.3	NULL
%	NULL
and	NULL
71.2	NULL
%	NULL
+	NULL
6	NULL
%	NULL
in	NULL
CD4*	NULL
PBT	NULL
treated	NULL
with	NULL
10-	NULL
M	NULL
and	NULL
3	NULL
X	NULL
10-	NULL
>	NULL
M	NULL
ASA	NULL
,	NULL
respectively	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

A	NULL
comparable	NULL
decrease	NULL
was	NULL
observed	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
the	NULL
same	NULL
concentrations	NULL
of	NULL
SA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
whereas	NULL
10-5	NULL
M	NULL
IM	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
the	NULL
Jurkat	NULL
human	NULL
T-cell	NULL
line	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
molecular	NULL
mechanisms	NULL
mediating	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
salicylates	NULL
on	NULL
IL-4	NULL
gene	NULL
expression	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effects	NULL
of	NULL
these	NULL
compounds	NULL
on	NULL
IL-4	NULL
promoter	NULL
activity	NULL
in	NULL
transiently	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
3C	NULL
,	NULL
ASA	NULL
(	NULL
10-5-10-3	NULL
M	NULL
)	NULL
caused	NULL
concentration-dependent	NULL
decrease	NULL
of	NULL
CAT	NULL
expression	NULL
driven	NULL
by	NULL
a	NULL
265-bp	NULL
IL-4	NULL
promoter	NULL
fragment	NULL
in	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
pg/mL	NULL
)	NULL
,	NULL
whereas	NULL
it	NULL
did	NULL
not	NULL
affect	NULL
constitutive	NULL
IL-4	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
degree	NULL
and	NULL
concentration	NULL
dependency	NULL
of	NULL
IL-4	NULL
promoter	NULL
inhibition	NULL
by	NULL
ASA	NULL
closely	NULL
matched	NULL
our	NULL
findings	NULL
on	NULL
IL-4	NULL
secretion	NULL
and	NULL
transcript	NULL
expression	NULL
in	NULL
PBT	NULL
(	NULL
Figures	NULL
1B	NULL
and	NULL
3B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
ASA	NULL
did	NULL
not	NULL
inhibit	NULL
,	NULL
but	NULL
slightly	NULL
enhanced	NULL
,	NULL
IL-2	NULL
promoter	NULL
activity	NULL
in	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
A23187	NULL
and	NULL
PMA	NULL
(	NULL
Figure	NULL
3C	NULL
)	NULL
.	NULL

Enhancement	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
was	NULL
especially	NULL
obvious	NULL
at	NULL
lower	NULL
concentrations	NULL
of	NULL
ASA	NULL
and	NULL
after	NULL
suboptimal	NULL
stimulation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

INHIBITION	NULL
OF	NULL
T-CELL	NULL
IL-4	NULL
EXPRESSION	NULL
BY	NULL
ASPIRIN	NULL
_	NULL
1745	NULL
IL-4	NULL
gene	NULL
inhibition	NULL
by	NULL
aspirin	NULL
is	NULL
not	NULL
associated	NULL
with	NULL
reduced	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
Significant	NULL
inhibition	NULL
of	NULL
IL-4	NULL
expression	NULL
was	NULL
observed	NULL
consistently	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
10-3	NULL
M	NULL
ASA	NULL
.	NULL

A	NULL
concentration	NULL
2.5	NULL
to	NULL
5	NULL
times	NULL
higher	NULL
was	NULL
previously	NULL
reported	NULL
to	NULL
be	NULL
necessary	NULL
for	NULL
comparable	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
DNA-binding	NULL
and	NULL
transcriptional	NULL
activities	NULL
.	NULL
``	NULL

''	NULL
To	NULL
determine	NULL
whether	NULL
lower	NULL
concentrations	NULL
of	NULL
salicylates	NULL
might	NULL
affect	NULL
NF-kB	NULL
activation	NULL
under	NULL
our	NULL
experimental	NULL
conditions	NULL
,	NULL
we	NULL
conducted	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
ASA	NULL
or	NULL
the	NULL
related	NULL
compound	NULL
SSA	NULL
,	NULL
a	NULL
known	NULL
potent	NULL
and	NULL
selective	NULL
inhibitor	NULL
of	NULL
NF-kB	NULL
.	NULL
``	NULL

Figure	NULL
4A	NULL
shows	NULL
an	NULL
experiment	NULL
in	NULL
which	NULL
stimulation	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
pg/mL	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
resulted	NULL
in	NULL
formation	NULL
of	NULL
2	NULL
complexes	NULL
on	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
a	NULL
consensus	NULL
NF-kB	NULL
element	NULL
from	NULL
the	NULL
-light-chain	NULL
gene	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
previous	NULL
findings	NULL
,	NULL
*	NULL
'	NULL
neither	NULL
complex	NULL
formed	NULL
when	NULL
extracts	NULL
from	NULL
cells	NULL
stimulated	NULL
with	NULL
A23187	NULL
alone	NULL
were	NULL
used	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Antibodies	NULL
raised	NULL
against	NULL
the	NULL
p65	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
p50	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
NF-kB	NULL
subunits	NULL
interfered	NULL
with	NULL
formation	NULL
of	NULL
both	NULL
complexes	NULL
.	NULL

Treatment	NULL
with	NULL
concentrations	NULL
of	NULL
ASA	NULL
that	NULL
significantly	NULL
inhibited	NULL
IL-4	NULL
expression	NULL
(	NULL
Figure	NULL
4A	NULL
shows	NULL
the	NULL
effect	NULL
of	NULL
2	NULL
X	NULL
10-	NULL
'	NULL
M	NULL
)	NULL
did	NULL
not	NULL
affect	NULL
formation	NULL
of	NULL
either	NULL
complex	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
a	NULL
similar	NULL
A	NULL
A23187+PMA	NULL
_	NULL
-	NULL
+	NULL
+	NULL
ASA	NULL
--	NULL
+	NULL
RE	NULL
CT	NULL
o-RTT	NULL
-s	NULL
RAT	NULL
TTT	NULL
IFN-y	NULL
|___	NULL
amana	NULL
TE	NULL
l	NULL
I	NULL
I	NULL
JGAPDH	NULL
B1OD	NULL
c	NULL
8	NULL
.	NULL

§	NULL
3	NULL
®	NULL
*	NULL
ES	NULL
n	NULL
Pe	NULL
[	NULL
_	NULL
Y	NULL
3	NULL
é	NULL
*	NULL
%	NULL
1	NULL
i	NULL
§	NULL
&	NULL
so	NULL
‘	NULL
®	NULL
§	NULL
_	NULL
Ca	NULL
10°	NULL
3x10°	NULL
IM	NULL
ASA	NULL
(	NULL
M	NULL
)	NULL
Figure	NULL
3	NULL
.	NULL

Inhibition	NULL
of	NULL
IL-4	NULL
gene	NULL
transcription	NULL
in	NULL
CD4+	NULL
T	NULL
cells	NULL
by	NULL
salicylates	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Purified	NULL
PBT	NULL
(	NULL
=	NULL
97	NULL
%	NULL
CD3+CD4*	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
ASA	NULL
(	NULL
10-	NULL
``	NULL
M	NULL
)	NULL
or	NULL
the	NULL
corresponding	NULL
amount	NULL
of	NULL
DMSO	NULL
carrier	NULL
(	NULL
0.1	NULL
%	NULL
)	NULL
before	NULL
stimulation	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
ug/mL	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
for	NULL
6	NULL
hours	NULL
.	NULL

Shown	NULL
are	NULL
the	NULL
results	NULL
of	NULL
RT-PCR	NULL
of	NULL
total	NULL
RNA	NULL
extracted	NULL
in	NULL
a	NULL
typical	NULL
experiment	NULL
using	NULL
primers	NULL
specific	NULL
for	NULL
the	NULL
indicated	NULL
cytokine	NULL
gene	NULL
transcripts	NULL
.	NULL

Shown	NULL
as	NULL
an	NULL
RNA	NULL
integrity	NULL
and	NULL
loading	NULL
control	NULL
is	NULL
the	NULL
expression	NULL
of	NULL
transcripts	NULL
of	NULL
the	NULL
GAPDH	NULL
gene	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
3	NULL
identical	NULL
experiments	NULL
using	NULL
ASA	NULL
or	NULL
SA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Real-time	NULL
RT-PCR	NULL
analysis	NULL
of	NULL
IL-4	NULL
RNA	NULL
expression	NULL
in	NULL
purified	NULL
PBT	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
ASA	NULL
or	NULL
with	NULL
10-5	NULL
M	NULL
IM	NULL
before	NULL
stimulation	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
pg/mL	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
for	NULL
6	NULL
hours	NULL
.	NULL

Standard	NULL
curves	NULL
for	NULL
IL-4	NULL
and	NULL
GAPDH	NULL
were	NULL
generated	NULL
by	NULL
serial	NULL
dilutions	NULL
of	NULL
PBT	NULL
total	NULL
RNA	NULL
in	NULL
separate	NULL
experiments	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
relative	NULL
IL-4	NULL
RNA	NULL
levels	NULL
were	NULL
calculated	NULL
.	NULL

Shown	NULL
is	NULL
the	NULL
mean	NULL
+	NULL
SEM	NULL
percentage	NULL
of	NULL
control	NULL
IL-4	NULL
expression	NULL
(	NULL
corresponding	NULL
to	NULL
2-AAC	NULL
;	NULL
x	NULL
100	NULL
)	NULL
in	NULL
3	NULL
independent	NULL
experiments	NULL
done	NULL
in	NULL
duplicate	NULL
.	NULL

The	NULL
asterisk	NULL
indicates	NULL
P	NULL
<	NULL
.05	NULL
relative	NULL
to	NULL
DMSO-treated	NULL
controls	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Jurkat	NULL
T	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
1L-4.265	NULL
or	NULL
1L-2.312	NULL
CAT	NULL
reporter	NULL
plasmids	NULL
were	NULL
treated	NULL
(	NULL
15	NULL
minutes	NULL
)	NULL
with	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
ASA	NULL
(	NULL
§	NULL
,	NULL
10-5	NULL
M	NULL
;	NULL
#	NULL
2	NULL
,	NULL
10-4	NULL
M	NULL
;	NULL
@	NULL
,	NULL
10-3	NULL
M	NULL
)	NULL
or	NULL
corresponding	NULL
amounts	NULL
of	NULL
DMSO	NULL
(	NULL
C	NULL
]	NULL
)	NULL
before	NULL
20-hour	NULL
stimulation	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
pg/mL	NULL
)	NULL
with	NULL
(	NULL
IL-2	NULL
)	NULL
or	NULL
without	NULL
(	NULL
IL-4	NULL
)	NULL
PMA	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
induction	NULL
of	NULL
intracellular	NULL
CAT	NULL
relative	NULL
to	NULL
unstimulated	NULL
controls	NULL
and	NULL
are	NULL
the	NULL
mean	NULL
+	NULL
SEM	NULL
results	NULL
from	NULL
4	NULL
independent	NULL
experiments	NULL
done	NULL
in	NULL
duplicate	NULL
.	NULL

The	NULL
asterisk	NULL
indicates	NULL
P	NULL
<	NULL
.05	NULL
(	NULL
Wilcoxon	NULL
test	NULL
)	NULL
relative	NULL
to	NULL
DMSO-treated	NULL
controls	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1746	NULL
_	NULL
CIANFERON	NULL
!	NULL

etal	NULL
concentration	NULL
of	NULL
SSA	NULL
(	NULL
2	NULL
X	NULL
107	NULL
``	NULL
M	NULL
)	NULL
was	NULL
,	NULL
as	NULL
reported	NULL
previously	NULL
,	NULL
``	NULL
sufficient	NULL
to	NULL
repress	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
in	NULL
Jurkat	NULL
cells	NULL
completely	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
SSA	NULL
on	NULL
activation	NULL
was	NULL
not	NULL
paralleled	NULL
by	NULL
an	NULL
increased	NULL
inhibitory	NULL
effect	NULL
,	NULL
relative	NULL
to	NULL
ASA	NULL
,	NULL
on	NULL
IL-4	NULL
promoter	NULL
activity	NULL
(	NULL
Figure	NULL
4B	NULL
)	NULL
.	NULL

ASA	NULL
and	NULL
SA	NULL
were	NULL
the	NULL
strongest	NULL
inhibitors	NULL
of	NULL
IL-4	NULL
promoter-driven	NULL
transcription	NULL
among	NULL
a	NULL
panel	NULL
of	NULL
structurally	NULL
related	NULL
compounds	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
,	NULL
SSA	NULL
and	NULL
2,5-dihydroxy-benzoic	NULL
acid	NULL
,	NULL
a	NULL
major	NULL
hydroxylated	NULL
ASA	NULL
metabolite	NULL
in	NULL
vivo	NULL
,	NULL
``	NULL
inhibited	NULL
promoter	NULL
activity	NULL
by	NULL
about	NULL
40	NULL
%	NULL
,	NULL
whereas	NULL
other	NULL
salicylates	NULL
were	NULL
completely	NULL
ineffective	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Figure	NULL
4B	NULL
shows	NULL
the	NULL
effects	NULL
of	NULL
identical	NULL
concentrations	NULL
of	NULL
ASA	NULL
and	NULL
SSA	NULL
(	NULL
2	NULL
X	NULL
10-	NULL
``	NULL
M	NULL
)	NULL
on	NULL
A23187-induced	NULL
CAT	NULL
expression	NULL
in	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
I1L-4.265	NULL
construct	NULL
.	NULL

SSA	NULL
was	NULL
significantly	NULL
less	NULL
effective	NULL
than	NULL
ASA	NULL
in	NULL
inhibiting	NULL
transcriptional	NULL
activity	NULL
of	NULL
this	NULL
construct	NULL
.	NULL

IL-4	NULL
promoter	NULL
activity	NULL
was	NULL
not	NULL
affected	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
5-aminosal-icylic	NULL
acid	NULL
(	NULL
5-ASA	NULL
)	NULL
,	NULL
the	NULL
salicylate	NULL
moiety	NULL
of	NULL
SSA	NULL
previously	NULL
found	NULL
to	NULL
be	NULL
a	NULL
relatively	NULL
ineffective	NULL
inhibitor	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL
``	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
an	NULL
analysis	NULL
of	NULL
IL-4	NULL
secretion	NULL
in	NULL
PBT	NULL
preparations	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
salicylate-targeted	NULL
region	NULL
in	NULL
the	NULL
human	NULL
IL-4	NULL
promoter	NULL
To	NULL
map	NULL
the	NULL
promoter	NULL
element	NULL
mediating	NULL
IL-4	NULL
gene	NULL
inhibition	NULL
by	NULL
ASA	NULL
,	NULL
we	NULL
generated	NULL
a	NULL
panel	NULL
of	NULL
IL-4	NULL
promoter	NULL
deletions	NULL
for	NULL
use	NULL
in	NULL
reporter	NULL
studies	NULL
.	NULL

ASA	NULL
and	NULL
SA	NULL
(	NULL
107	NULL
M	NULL
)	NULL
were	NULL
equally	NULL
effective	NULL
at	NULL
inhibiting	NULL
the	NULL
activation	NULL
of	NULL
IL-4	NULL
promoter	NULL
constructs	NULL
truncated	NULL
at	NULL
bp	NULL
-265	NULL
through	NULL
-145	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Figure	NULL
5A	NULL
shows	NULL
that	NULL
CAT	NULL
expression	NULL
was	NULL
significantly	NULL
inhibited	NULL
in	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
a	NULL
construct	NULL
carrying	NULL
an	NULL
IL-4	NULL
promoter	NULL
fragment	NULL
spanning	NULL
bp	NULL
-145	NULL
to	NULL
+55	NULL
(	NULL
IL-4.145	NULL
)	NULL
and	NULL
treated	NULL
with	NULL
ASA	NULL
or	NULL
SA	NULL
(	NULL
10-2	NULL
M	NULL
)	NULL
but	NULL
not	NULL
FBP	NULL
(	NULL
10-5	NULL
M	NULL
)	NULL
.	NULL

The	NULL
same	NULL
concentrations	NULL
of	NULL
ASA	NULL
and	NULL
FBP	NULL
but	NULL
not	NULL
SA	NULL
up-regulated	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
an	NULL
IL-4	NULL
promoter	NULL
construct	NULL
(	NULL
IL-4.95	NULL
)	NULL
lacking	NULL
bp	NULL
-145	NULL
to	NULL
-96	NULL
(	NULL
Figure	NULL
5A	NULL
)	NULL
.	NULL

This	NULL
indicated	NULL
that	NULL
an	NULL
element	NULL
mediating	NULL
inhibition	NULL
of	NULL
IL-4	NULL
transcription	NULL
by	NULL
ASA	NULL
and	NULL
SA	NULL
is	NULL
located	NULL
between	NULL
bp	NULL
-145	NULL
and	NULL
-96	NULL
of	NULL
the	NULL
human	NULL
A	NULL
pmso	NULL
_	NULL
&	NULL
&	NULL
B	NULL
<	NULL
A23187	NULL
-	NULL
+	NULL
+	NULL
4	NULL
+	NULL
+	NULL
+	NULL
PMA	NULL
-	NULL
+	NULL
4	NULL
4+	NULL
-	NULL
+	NULL
+	NULL
120	NULL
C	NULL
|	NULL
G	NULL
801	NULL
|	NULL
[	NULL
a	NULL
*	NULL
|	NULL
4	NULL
.	NULL

|	NULL
o	NULL
s	NULL
5:5	NULL
*	NULL
g	NULL
**	NULL
I	NULL
|	NULL
a	NULL
|	NULL
L	NULL
20	NULL
|	NULL
o	NULL
e	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
ASA	NULL
_	NULL
SSA	NULL
-	NULL
5-ASA	NULL
Figure	NULL
4	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
ASA	NULL
and	NULL
SSA	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Cells	NULL
were	NULL
treated	NULL
with	NULL
ASA	NULL
(	NULL
2	NULL
x	NULL
10-	NULL
``	NULL
M	NULL
)	NULL
,	NULL
SSA	NULL
(	NULL
2	NULL
x	NULL
10~	NULL
``	NULL
M	NULL
)	NULL
,	NULL
or	NULL
corresponding	NULL
amounts	NULL
of	NULL
DMSO	NULL
carrier	NULL
before	NULL
stimulation	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
g/mL	NULL
)	NULL
with	NULL
or	NULL
without	NULL
PMA	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
for	NULL
2	NULL
hours	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
each	NULL
sample	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
radiolabeled	NULL
consensus	NULL
NF-kB	NULL
oligonucleotide	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
2	NULL
complexes	NULL
induced	NULL
by	NULL
stimulation	NULL
with	NULL
A23187	NULL
and	NULL
PMA	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
but	NULL
not	NULL
A23187	NULL
alone	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Both	NULL
complexes	NULL
contained	NULL
NF-kB	NULL
molecular	NULL
species	NULL
as	NULL
detected	NULL
by	NULL
coincubation	NULL
with	NULL
anti-p65	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
anti-p50	NULL
antibodies	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Jurkat	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
1L-4.265	NULL
plasmid	NULL
were	NULL
treated	NULL
(	NULL
15	NULL
minutes	NULL
)	NULL
with	NULL
ASA	NULL
(	NULL
2	NULL
x	NULL
10-2	NULL
M	NULL
)	NULL
,	NULL
SSA	NULL
(	NULL
2	NULL
x	NULL
10-	NULL
``	NULL
M	NULL
)	NULL
,	NULL
5-ASA	NULL
(	NULL
2	NULL
x	NULL
10-3	NULL
M	NULL
)	NULL
,	NULL
or	NULL
corresponding	NULL
amounts	NULL
of	NULL
DMSO	NULL
before	NULL
20-hour	NULL
stimulation	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
mg/mL	NULL
)	NULL
.	NULL

The	NULL
mean	NULL
+	NULL
SEM	NULL
percentage	NULL
of	NULL
control	NULL
CAT	NULL
expression	NULL
in	NULL
4	NULL
independent	NULL
experiments	NULL
done	NULL
in	NULL
duplicate	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
asterisk	NULL
indicates	NULL
P	NULL
<	NULL
.05	NULL
(	NULL
Wilcoxon	NULL
test	NULL
)	NULL
relative	NULL
to	NULL
samples	NULL
treated	NULL
with	NULL
DMSO	NULL
.	NULL

BLOOD	NULL
,	NULL
15	NULL
MARCH	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
6	NULL
IL-4.115	NULL
-	NULL
+	NULL
D	NULL
>	NULL
a	NULL
IL-4.135	NULL
``	NULL
azsier	NULL
-o	NULL
40	NULL
%	NULL
+	NULL
ASA	NULL
-o-	NULL
%	NULL
+	NULL
1	NULL
a	NULL
6	NULL
3	NULL
Percent	NULL
of	NULL
control	NULL
a	NULL
4	NULL
IL-4.95	NULL
1	NULL
as	NULL
~145	NULL
-11	NULL
a	NULL
|	NULL
-	NULL
|	NULL
.	NULL

.	NULL

.	NULL

TTACCTGTTTGTGAGGCATTTTTT	NULL
CT	NULL
UCT	NULL
GGAAGAGAGGT	NULL
G	NULL
.1'GA	NULL
‘	NULL
I'TEGICCCEAAGHF-fgIGﬁAATETG	NULL
he	NULL
EBS	NULL
E2	NULL
CCAAT	NULL
E	NULL
TRE	NULL
.h	NULL
--	NULL
IT	NULL
My	NULL
ts	NULL
I	NULL
Figure	NULL
5	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
salicylate-responsive	NULL
region	NULL
in	NULL
the	NULL
human	NULL
IL-4	NULL
promoter	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
indicated	NULL
human	NULL
IL-4	NULL
promoter	NULL
deletional	NULL
constructs	NULL
were	NULL
treated	NULL
with	NULL
ASA	NULL
(	NULL
C	NULL
]	NULL
,	NULL
10	NULL
``	NULL
M	NULL
)	NULL
,	NULL
SA	NULL
(	NULL
#	NULL
,	NULL
10~	NULL
``	NULL
M	NULL
)	NULL
,	NULL
or	NULL
FBP	NULL
(	NULL
ill	NULL
,	NULL
10-5	NULL
M	NULL
)	NULL
before	NULL
20-hour	NULL
stimulation	NULL
with	NULL
0.5	NULL
pg/mL	NULL
A23187	NULL
.	NULL

The	NULL
mean	NULL
+	NULL
SEM	NULL
percentage	NULL
of	NULL
control	NULL
A23187-induced	NULL
CAT	NULL
expression	NULL
(	NULL
broken	NULL
horizontal	NULL
line	NULL
)	NULL
in	NULL
3	NULL
independent	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
asterisk	NULL
indicates	NULL
P	NULL
<	NULL
.05	NULL
(	NULL
Wilcoxon	NULL
test	NULL
)	NULL
relative	NULL
to	NULL
DMSO-treated	NULL
controls	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
the	NULL
human	NULL
IL-4	NULL
promoter	NULL
and	NULL
the	NULL
sequence	NULL
required	NULL
for	NULL
its	NULL
inhibition	NULL
by	NULL
salicylates	NULL
.	NULL

Open	NULL
and	NULL
solid	NULL
boxes	NULL
indicate	NULL
the	NULL
relative	NULL
positions	NULL
of	NULL
positive	NULL
and	NULL
negative	NULL
regulatory	NULL
elements	NULL
,	NULL
respectively	NULL
,	NULL
that	NULL
have	NULL
been	NULL
identified	NULL
.	NULL

ISRE	NULL
indicates	NULL
IFN	NULL
stimulation-response	NULL
element	NULL
;	NULL
MARE	NULL
,	NULL
c-Maf	NULL
response	NULL
element	NULL
;	NULL
NRE	NULL
,	NULL
negative	NULL
regulatory	NULL
element	NULL
;	NULL
and	NULL
OAP	NULL
,	NULL
octamer-associated	NULL
protein	NULL
.	NULL

Schematically	NULL
shown	NULL
below	NULL
are	NULL
3	NULL
oligonucleotides	NULL
(	NULL
IL-4.155	NULL
,	NULL
IL-4.135	NULL
,	NULL
and	NULL
IL-4.115	NULL
)	NULL
,	NULL
spanning	NULL
putative	NULL
promoter	NULL
elements	NULL
in	NULL
the	NULL
salicylate-targeted	NULL
region	NULL
,	NULL
that	NULL
were	NULL
used	NULL
as	NULL
probes	NULL
in	NULL
EMSAs	NULL
.	NULL

TRE	NULL
indicates	NULL
tetradecanoylphorbol	NULL
acetate-response	NULL
element	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
ASA	NULL
(	NULL
10	NULL
~*	NULL
M	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
or	NULL
DMSO	NULL
carrier	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
)	NULL
before	NULL
stimulation	NULL
with	NULL
A23187	NULL
(	NULL
0.5	NULL
mg/mL	NULL
)	NULL
for	NULL
2	NULL
hours	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
labeled	NULL
1L-4.155	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
IL-4.135	NULL
,	NULL
or	NULL
IL-4.115	NULL
oligonucleotides	NULL
.	NULL

The	NULL
arrow	NULL
at	NULL
left	NULL
indicates	NULL
an	NULL
A23187-induced	NULL
IL-4.135-binding	NULL
complex	NULL
whose	NULL
formation	NULL
was	NULL
markedly	NULL
reduced	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
ASA	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

IL-4	NULL
promoter	NULL
and	NULL
that	NULL
a	NULL
COX-related	NULL
mechanism	NULL
might	NULL
account	NULL
for	NULL
increased	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IL-4.95	NULL
construct	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
ASA	NULL
or	NULL
FBP	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
salicylate-targeted	NULL
region	NULL
of	NULL
the	NULL
human	NULL
IL-4	NULL
promoter	NULL
is	NULL
shown	NULL
in	NULL
Figure	NULL
5B	NULL
.	NULL

Integrity	NULL
of	NULL
this	NULL
region	NULL
appears	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
maximal	NULL
IL-4	NULL
promoter	NULL
activity	NULL
in	NULL
murine	NULL
and	NULL
human	NULL
T	NULL
cells.4	NULL
>	NULL
**	NULL
An	NULL
inverted	NULL
CCAAT	NULL
box	NULL
at	NULL
bp	NULL
-114	NULL
is	NULL
the	NULL
only	NULL
element	NULL
in	NULL
this	NULL
region	NULL
of	NULL
the	NULL
IL-4	NULL
promoter	NULL
that	NULL
has	NULL
been	NULL
characterized	NULL
,	NULL
and	NULL
it	NULL
binds	NULL
the	NULL
ubiquitous	NULL
and	NULL
constitutive	NULL
factor	NULL
CBF	NULL
,	NULL
also	NULL
known	NULL
as	NULL
NF-Y	NULL
.	NULL

However	NULL
,	NULL
sequence	NULL
analysis	NULL
revealed	NULL
the	NULL
existence	NULL
of	NULL
additional	NULL
putative	NULL
binding	NULL
sites	NULL
for	NULL
several	NULL
plausible	NULL
candidates	NULL
for	NULL
IL-4	NULL
gene	NULL
regulation	NULL
in	NULL
differentiated	NULL
T	NULL
cells	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
.	NULL

These	NULL
include	NULL
an	NULL
80	NULL
%	NULL
conserved	NULL
Ets-binding	NULL
site	NULL
at	NULL
bp	NULL
-	NULL
128	NULL
,	NULL
``	NULL
an	NULL
E	NULL
box	NULL
(	NULL
CANNTG	NULL
)	NULL
at	NULL
bp	NULL
-103	NULL
,	NULL
*5	NULL
and	NULL
an	NULL
E2	NULL
box	NULL
at	NULL
bp	NULL
-119	NULL
that	NULL
is	NULL
known	NULL
to	NULL
be	NULL
recognized	NULL
by	NULL
multi-zinc-finger	NULL
factors	NULL
such	NULL
as	NULL
ZEB	NULL
.	NULL

*	NULL
``	NULL
Although	NULL
factors	NULL
binding	NULL
to	NULL
such	NULL
elements	NULL
have	NULL
been	NULL
found	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
T-cell	NULL
pathophysiology	NULL
and	NULL
the	NULL
development	NULL
of	NULL
immune	NULL
and	NULL
inflammatory	NULL
responses	NULL
,	NULL
none	NULL
have	NULL
yet	NULL
been	NULL
characterized	NULL
as	NULL
a	NULL
regulator	NULL
of	NULL
IL-4	NULL
expression	NULL
or	NULL
a	NULL
salicylate	NULL
target	NULL
.	NULL

To	NULL
understand	NULL
the	NULL
relative	NULL
contribution	NULL
of	NULL
each	NULL
of	NULL
these	NULL
elements	NULL
and	NULL
their	NULL
cognate	NULL
factors	NULL
to	NULL
IL-4	NULL
transcriptional	NULL
regulation	NULL
by	NULL
salicylates	NULL
,	NULL
we	NULL
generated	NULL
3	NULL
oligonucleotides	NULL
spanning	NULL
overlapping	NULL
sequences	NULL
in	NULL
a	NULL
region	NULL
including	NULL
bp	NULL
-155	NULL
to	NULL
-90	NULL
of	NULL
the	NULL
IL-4	NULL
promoter	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
.	NULL

In	NULL
EMSAs	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
,	NULL
treatment	NULL
with	NULL
ASA	NULL
(	NULL
10~-	NULL
M	NULL
)	NULL
interfered	NULL
with	NULL
the	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
15	NULL
MARCH	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
6	NULL
binding	NULL
of	NULL
an	NULL
A23187-induced	NULL
complex	NULL
(	NULL
Figure	NULL
5C	NULL
,	NULL
arrow	NULL
)	NULL
to	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
bp	NULL
-135	NULL
to	NULL
-110	NULL
(	NULL
IL-4.135	NULL
;	NULL
lane	NULL
4	NULL
)	NULL
but	NULL
did	NULL
not	NULL
substantially	NULL
affect	NULL
any	NULL
of	NULL
the	NULL
complexes	NULL
forming	NULL
on	NULL
bp	NULL
-115	NULL
to	NULL
-90	NULL
of	NULL
the	NULL
IL-4	NULL
promoter	NULL
(	NULL
IL-4.115	NULL
;	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

ASA	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
pattern	NULL
of	NULL
complex	NULL
formation	NULL
in	NULL
EMSAs	NULL
using	NULL
an	NULL
1IL-4.155	NULL
probe	NULL
or	NULL
an	NULL
oligonucleotide	NULL
centered	NULL
on	NULL
the	NULL
CCAAT	NULL
box	NULL
(	NULL
IL-4.CCAAT	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
extracts	NULL
from	NULL
A23187-	NULL
and	NULL
PMA-stimulated	NULL
,	NULL
ASA-	NULL
or	NULL
SA-treated	NULL
PBT	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
further	NULL
characterize	NULL
the	NULL
ASA-responsive	NULL
complex	NULL
forming	NULL
on	NULL
IL-4.135	NULL
,	NULL
we	NULL
tested	NULL
several	NULL
antibodies	NULL
,	NULL
including	NULL
IgG	NULL
specific	NULL
for	NULL
the	NULL
factors	NULL
Ets-1	NULL
and	NULL
Ets-2	NULL
,	NULL
NFAT-1	NULL
,	NULL
and	NULL
CBF	NULL
,	NULL
in	NULL
EMSAs	NULL
using	NULL
extracts	NULL
from	NULL
activated	NULL
Jurkat	NULL
cells	NULL
or	NULL
PBT	NULL
.	NULL

None	NULL
of	NULL
these	NULL
affected	NULL
complex	NULL
formation	NULL
in	NULL
these	NULL
experiments	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Discussion	NULL
This	NULL
study	NULL
is	NULL
the	NULL
first	NULL
to	NULL
find	NULL
that	NULL
therapeutic	NULL
concentrations	NULL
of	NULL
ASA	NULL
``	NULL
significantly	NULL
inhibit	NULL
IL-4	NULL
gene	NULL
expression	NULL
in	NULL
activated	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

Inhibition	NULL
of	NULL
IL-4	NULL
secretion	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
ASA	NULL
was	NULL
not	NULL
associated	NULL
with	NULL
reduced	NULL
viability	NULL
,	NULL
impaired	NULL
basic	NULL
biochemical	NULL
and	NULL
molecular	NULL
functions	NULL
,	NULL
or	NULL
expression	NULL
of	NULL
early	NULL
apoptotic	NULL
markers	NULL
.	NULL

Indeed	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
stimulants	NULL
used	NULL
,	NULL
IL-2	NULL
production	NULL
was	NULL
not	NULL
inhibited	NULL
or	NULL
was	NULL
moderately	NULL
enhanced	NULL
after	NULL
treatment	NULL
with	NULL
ASA	NULL
.	NULL

Similarly	NULL
,	NULL
ASA	NULL
did	NULL
not	NULL
affect	NULL
expression	NULL
of	NULL
the	NULL
effector	NULL
cytokines	NULL
IL-13	NULL
and	NULL
IFN-y	NULL
in	NULL
CD4+*	NULL
PBT	NULL
.	NULL

The	NULL
results	NULL
of	NULL
our	NULL
experiments	NULL
in	NULL
transiently	NULL
transfected	NULL
Jurkat	NULL
T	NULL
cells	NULL
indicate	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
ASA	NULL
on	NULL
IL-4	NULL
expression	NULL
is	NULL
exerted	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
.	NULL

Our	NULL
findings	NULL
can	NULL
not	NULL
be	NULL
accounted	NULL
for	NULL
by	NULL
the	NULL
reported	NULL
inhibitory	NULL
effects	NULL
of	NULL
ASA	NULL
on	NULL
PG	NULL
generation	NULL
or	NULL
NF-KB	NULL
activation	NULL
,	NULL
``	NULL
and	NULL
they	NULL
suggest	NULL
involvement	NULL
of	NULL
an	NULL
alternative	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
salicylates	NULL
.	NULL

To	NULL
our	NULL
knowledge	NULL
,	NULL
our	NULL
experiments	NULL
using	NULL
purified	NULL
PBT	NULL
and	NULL
Jurkat	NULL
cells	NULL
provide	NULL
the	NULL
first	NULL
evidence	NULL
that	NULL
CD4*	NULL
T	NULL
cells	NULL
may	NULL
be	NULL
a	NULL
direct	NULL
target	NULL
of	NULL
ASA	NULL
and	NULL
related	NULL
compounds	NULL
.	NULL

The	NULL
hypothesis	NULL
that	NULL
inhibition	NULL
of	NULL
immunomodulatory	NULL
PGs	NULL
mediates	NULL
the	NULL
effect	NULL
of	NULL
ASA	NULL
on	NULL
IL-4	NULL
production	NULL
in	NULL
these	NULL
cells	NULL
!	NULL
``	NULL

was	NULL
not	NULL
validated	NULL
by	NULL
our	NULL
experiments	NULL
using	NULL
structurally	NULL
unrelated	NULL
COX	NULL
inhibitors	NULL
(	NULL
Figures	NULL
2	NULL
and	NULL
5A	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
produce	NULL
negligible	NULL
amounts	NULL
of	NULL
known	NULL
COX	NULL
products	NULL
,	NULL
with	NULL
almost	NULL
100-fold-lower	NULL
PGE	NULL
,	NULL
levels	NULL
than	NULL
required	NULL
to	NULL
modulate	NULL
cytokine	NULL
produc-tion	NULL
.	NULL

*	NULL
``	NULL
*+38	NULL
Previous	NULL
studies	NULL
using	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
or	NULL
unfractionated	NULL
PBT	NULL
preparations	NULL
showed	NULL
that	NULL
submillimolar	NULL
concentrations	NULL
of	NULL
ASA	NULL
can	NULL
enhance	NULL
several	NULL
aspects	NULL
of	NULL
mitogen-induced	NULL
T-cell	NULL
activation	NULL
,	NULL
including	NULL
proliferative	NULL
responses	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
IFN-y	NULL
and	NULL
IL-2	NULL
.	NULL
``	NULL

Although	NULL
these	NULL
effects	NULL
of	NULL
ASA	NULL
have	NULL
been	NULL
related	NULL
to	NULL
its	NULL
ability	NULL
to	NULL
suppress	NULL
production	NULL
of	NULL
monocyte-derived	NULL
PGs	NULL
,	NULL
``	NULL
prolonged	NULL
(	NULL
96-hour	NULL
)	NULL
incubation	NULL
with	NULL
several	NULL
nonsali-cylic	NULL
NSAIDs	NULL
was	NULL
found	NULL
to	NULL
enhance	NULL
mitogen-induced	NULL
T-cell	NULL
proliferation	NULL
and	NULL
IL-2	NULL
production	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
monocytes	NULL
.	NULL
``	NULL

However	NULL
,	NULL
this	NULL
finding	NULL
was	NULL
not	NULL
confirmed	NULL
in	NULL
subsequent	NULL
studies	NULL
of	NULL
long-term	NULL
(	NULL
>	NULL
72-hour	NULL
)	NULL
in	NULL
vitro	NULL
effects	NULL
of	NULL
ASA	NULL
and	NULL
SA	NULL
on	NULL
monocyte-depleted	NULL
PBT	NULL
preparations	NULL
.	NULL
``	NULL

In	NULL
our	NULL
study	NULL
,	NULL
which	NULL
focused	NULL
on	NULL
the	NULL
short-term	NULL
effects	NULL
of	NULL
ASA	NULL
on	NULL
isolated	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
IL-2	NULL
expression	NULL
and	NULL
promoter	NULL
activity	NULL
were	NULL
enhanced	NULL
only	NULL
under	NULL
specific	NULL
stimulation	NULL
conditions	NULL
,	NULL
and	NULL
lower	NULL
concentrations	NULL
of	NULL
ASA	NULL
(	NULL
10-5-107+	NULL
M	NULL
)	NULL
appeared	NULL
to	NULL
be	NULL
more	NULL
effective	NULL
,	NULL
presumably	NULL
because	NULL
of	NULL
the	NULL
concentration-dependent	NULL
involvement	NULL
of	NULL
opposite	NULL
mechanisms	NULL
of	NULL
action	NULL
.	NULL

None	NULL
of	NULL
the	NULL
concentrations	NULL
of	NULL
ASA	NULL
used	NULL
in	NULL
our	NULL
study	NULL
significantly	NULL
affected	NULL
production	NULL
of	NULL
IL-13	NULL
and	NULL
IFN-y	NULL
in	NULL
CD4+*	NULL
PBT	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
findings	NULL
indicate	NULL
that	NULL
IL-4	NULL
is	NULL
a	NULL
preferential	NULL
target	NULL
of	NULL
INHIBITION	NULL
OF	NULL
T-CELL	NULL
IL-4	NULL
EXPRESSION	NULL
BY	NULL
ASPIRIN	NULL
_	NULL
1747	NULL
salicylates	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
thus	NULL
pointing	NULL
to	NULL
the	NULL
existence	NULL
of	NULL
unique	NULL
molecular	NULL
pathways	NULL
that	NULL
regulate	NULL
expression	NULL
of	NULL
this	NULL
cytokine	NULL
gene	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Several	NULL
reports	NULL
indicated	NULL
that	NULL
NSAIDs	NULL
,	NULL
including	NULL
ASA	NULL
and	NULL
SA	NULL
,	NULL
can	NULL
induce	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
Ca+*	NULL
and	NULL
the	NULL
transient	NULL
activation	NULL
of	NULL
PKC	NULL
in	NULL
T	NULL
cells	NULL
.	NULL
'	NULL

''	NULL
2	NULL
``	NULL
These	NULL
2	NULL
events	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
antigen-	NULL
and	NULL
mitogen-dependent	NULL
T-cell	NULL
activation	NULL
and	NULL
cytokine	NULL
gene	NULL
expression	NULL
.	NULL
``	NULL

''	NULL
Indeed	NULL
,	NULL
one	NULL
study	NULL
found	NULL
that	NULL
FBP	NULL
can	NULL
activate	NULL
the	NULL
Ca+**-	NULL
or	NULL
PKC-dependent	NULL
factors	NULL
NFAT	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
NF-kB	NULL
in	NULL
unfractionated	NULL
PBT	NULL
.	NULL

*	NULL
However	NULL
,	NULL
the	NULL
relation	NULL
between	NULL
these	NULL
findings	NULL
and	NULL
the	NULL
results	NULL
of	NULL
our	NULL
study	NULL
is	NULL
unclear	NULL
.	NULL

Although	NULL
these	NULL
phenomena	NULL
have	NULL
been	NULL
cited	NULL
to	NULL
explain	NULL
the	NULL
comitogenic	NULL
potential	NULL
of	NULL
ASA	NULL
and	NULL
other	NULL
NSAIDs	NULL
,	NULL
they	NULL
are	NULL
not	NULL
necessarily	NULL
associated	NULL
with	NULL
T-cell	NULL
activation	NULL
and	NULL
IL-2	NULL
production	NULL
,	NULL
presumably	NULL
because	NULL
of	NULL
their	NULL
intrinsically	NULL
transient	NULL
nature	NULL
.	NULL
``	NULL

''	NULL
Furthermore	NULL
,	NULL
the	NULL
idea	NULL
that	NULL
NSAIDs	NULL
,	NULL
particularly	NULL
ASA	NULL
and	NULL
SA	NULL
,	NULL
function	NULL
as	NULL
adjuvants	NULL
in	NULL
host	NULL
immune	NULL
responses	NULL
was	NULL
challenged	NULL
in	NULL
studies	NULL
showing	NULL
the	NULL
COX-independent	NULL
inhibitory	NULL
effect	NULL
of	NULL
ASA	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
NF-kB	NULL
and	NULL
other	NULL
critical	NULL
transcriptional	NULL
activators	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
other	NULL
types	NULL
of	NULL
cells.8	NULL
!	NULL

®	NULL
ASA	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
nuclear	NULL
translocation	NULL
at	NULL
much	NULL
higher	NULL
concentrations	NULL
(	NULL
>	NULL
2.5	NULL
X	NULL
10-	NULL
M	NULL
)	NULL
than	NULL
its	NULL
reported	NULL
concentration	NULL
that	NULL
inhibits	NULL
by	NULL
50	NULL
%	NULL
COX-1	NULL
(	NULL
~2	NULL
X	NULL
10-5	NULL
M	NULL
)	NULL
and	NULL
COX-2	NULL
(	NULL
~3	NULL
xX	NULL
10-4	NULL
M	NULL
)	NULL
.	NULL

``	NULL
®	NULL
Indeed	NULL
,	NULL
higher	NULL
doses	NULL
of	NULL
ASA	NULL
than	NULL
are	NULL
required	NULL
to	NULL
inhibit	NULL
PG	NULL
generation	NULL
are	NULL
used	NULL
to	NULL
treat	NULL
chronic	NULL
inflammatory	NULL
diseases.©	NULL
However	NULL
,	NULL
salicylate-related	NULL
toxicity	NULL
(	NULL
eg	NULL
,	NULL
tinnitus	NULL
)	NULL
can	NULL
occur	NULL
with	NULL
SA	NULL
plasma	NULL
levels	NULL
as	NULL
low	NULL
as	NULL
1.2	NULL
X	NULL
10-	NULL
``	NULL
M.	NULL
``	NULL
Significant	NULL
inhibition	NULL
of	NULL
IL-4	NULL
expression	NULL
or	NULL
promoter	NULL
activity	NULL
in	NULL
our	NULL
study	NULL
was	NULL
obtained	NULL
with	NULL
ASA	NULL
or	NULL
SA	NULL
concentrations	NULL
of	NULL
10-3	NULL
M	NULL
or	NULL
lower	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
,	NULL
well	NULL
within	NULL
the	NULL
reported	NULL
therapeutic	NULL
range	NULL
for	NULL
these	NULL
compounds	NULL
(	NULL
0.8-1.7	NULL
X	NULL
10-3	NULL
M	NULL
)	NULL
.	NULL
``	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
confirmed	NULL
that	NULL
these	NULL
concentrations	NULL
of	NULL
ASA	NULL
are	NULL
not	NULL
sufficient	NULL
to	NULL
affect	NULL
NF-KB	NULL
DNA-binding	NULL
and	NULL
transcriptional	NULL
activity	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.8	NULL
``	NULL
°	NULL
On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
the	NULL
structurally	NULL
related	NULL
compound	NULL
SSA	NULL
,	NULL
although	NULL
it	NULL
caused	NULL
,	NULL
as	NULL
reported	NULL
previously	NULL
,	NULL
``	NULL
``	NULL
almost	NULL
complete	NULL
inhibition	NULL
of	NULL
NE-xB	NULL
DNA	NULL
binding	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
,	NULL
was	NULL
a	NULL
significantly	NULL
less	NULL
effective	NULL
inhibitor	NULL
of	NULL
IL-4	NULL
promoter	NULL
activity	NULL
than	NULL
ASA	NULL
or	NULL
SA	NULL
(	NULL
Figure	NULL
4B	NULL
)	NULL
.	NULL

ASA	NULL
effectively	NULL
inhibited	NULL
IL-4	NULL
promoter	NULL
activation	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
a	NULL
Ca+*	NULL
ionophore	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
engagement	NULL
of	NULL
Ca+**-delivered	NULL
signals	NULL
is	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
maximal	NULL
activation	NULL
of	NULL
the	NULL
IL-4	NULL
gene	NULL
in	NULL
several	NULL
T-cell	NULL
lines	NULL
and	NULL
clones	NULL
,	NULL
including	NULL
Jurkat	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
our	NULL
study	NULL
confirmed	NULL
that	NULL
PKC	NULL
coactivation	NULL
by	NULL
PMA	NULL
is	NULL
a	NULL
stringent	NULL
requirement	NULL
for	NULL
NF-kB	NULL
induction	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.4	NULL
'	NULL
Although	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
necessary	NULL
activator	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
,	NULL
``	NULL
it	NULL
contributes	NULL
significantly	NULL
to	NULL
IL-4	NULL
down-regulation	NULL
by	NULL
PMA	NULL
.	NULL

*	NULL
``	NULL
In	NULL
our	NULL
study	NULL
,	NULL
however	NULL
,	NULL
ASA	NULL
and	NULL
SA	NULL
inhibited	NULL
IL-4	NULL
expression	NULL
without	NULL
affecting	NULL
IL-2	NULL
expression	NULL
,	NULL
at	NULL
a	NULL
concentration	NULL
(	NULL
3	NULL
X	NULL
10-	NULL
>	NULL
M	NULL
)	NULL
reported	NULL
to	NULL
cause	NULL
at	NULL
least	NULL
50	NULL
%	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B-induced	NULL
transcription.©	NULL
Taken	NULL
together	NULL
,	NULL
our	NULL
findings	NULL
indicate	NULL
that	NULL
a	NULL
factor	NULL
other	NULL
than	NULL
NF-KB	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
salicylates	NULL
on	NULL
IL-4	NULL
transcription	NULL
.	NULL

The	NULL
mechanisms	NULL
regulating	NULL
IL-4	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
and	NULL
murine	NULL
CD4*	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
the	NULL
focus	NULL
of	NULL
intensive	NULL
investigation	NULL
during	NULL
the	NULL
past	NULL
few	NULL
years	NULL
.	NULL
``	NULL

Members	NULL
of	NULL
the	NULL
NFAT	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
are	NULL
thought	NULL
to	NULL
have	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
antigen-dependent	NULL
IL-4	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
cells.59	NULL
``	NULL
4	NULL
Although	NULL
the	NULL
known	NULL
NFAT	NULL
molecular	NULL
species	NULL
appear	NULL
to	NULL
be	NULL
expressed	NULL
at	NULL
similar	NULL
levels	NULL
in	NULL
Th1	NULL
and	NULL
Th2	NULL
cells	NULL
,	NULL
NFAT-directed	NULL
IL-4	NULL
transcription	NULL
is	NULL
preferentially	NULL
induced	NULL
in	NULL
Th2	NULL
cells	NULL
,	NULL
presumably	NULL
because	NULL
of	NULL
the	NULL
involvement	NULL
of	NULL
lineage-restricted	NULL
coactiva-tors	NULL
.	NULL
``	NULL

NFAT	NULL
,	NULL
however	NULL
,	NULL
is	NULL
not	NULL
a	NULL
reasonable	NULL
candidate	NULL
for	NULL
a	NULL
molecular	NULL
target	NULL
of	NULL
salicylates	NULL
in	NULL
our	NULL
experimental	NULL
system	NULL
.	NULL

Ca+**-and	NULL
calcineurin-dependent	NULL
activation	NULL
of	NULL
NFAT	NULL
also	NULL
appears	NULL
to	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1748	NULL
_	NULL
CIANFERON	NULL
!	NULL

etal	NULL
be	NULL
a	NULL
requirement	NULL
for	NULL
expression	NULL
of	NULL
IFN-y	NULL
,	NULL
IL-2	NULL
,	NULL
and	NULL
perhaps	NULL
1L-13.5	NULL
%	NULL
5*5	NULL
$	NULL
.5	NULL
``	NULL
Moreover	NULL
,	NULL
increased	NULL
NFAT	NULL
nuclear	NULL
mobilization	NULL
and	NULL
DNA	NULL
binding	NULL
after	NULL
treatment	NULL
with	NULL
FBP	NULL
was	NULL
observed	NULL
in	NULL
isolated	NULL
PBT	NULL
.	NULL

*	NULL
``	NULL
We	NULL
previously	NULL
found	NULL
that	NULL
ASA	NULL
can	NULL
up-regulate	NULL
NFAT	NULL
nuclear	NULL
expression	NULL
and	NULL
NFAT-driven	NULL
transcription	NULL
.	NULL
``	NULL

''	NULL
ASA	NULL
,	NULL
but	NULL
not	NULL
SA	NULL
or	NULL
SSA	NULL
,	NULL
increased	NULL
formation	NULL
of	NULL
an	NULL
NFAT-1-containing	NULL
complex	NULL
on	NULL
the	NULL
P1	NULL
element	NULL
,	NULL
which	NULL
was	NULL
paralleled	NULL
by	NULL
sustained	NULL
nuclear	NULL
expression	NULL
of	NULL
NFAT-1	NULL
in	NULL
Western	NULL
blotting	NULL
and	NULL
immunofluorescence	NULL
experiments	NULL
using	NULL
PBT	NULL
or	NULL
Jurkat	NULL
cells	NULL
.	NULL
``	NULL

These	NULL
effects	NULL
,	NULL
shared	NULL
with	NULL
other	NULL
COX	NULL
inhibitors	NULL
,	NULL
such	NULL
as	NULL
IM	NULL
and	NULL
FBP	NULL
,	NULL
likely	NULL
account	NULL
for	NULL
increased	NULL
transcriptional	NULL
activity	NULL
of	NULL
a	NULL
minimal	NULL
IL-4	NULL
promoter	NULL
construct	NULL
(	NULL
IL-4.95	NULL
;	NULL
Figure	NULL
5A	NULL
)	NULL
but	NULL
are	NULL
clearly	NULL
dissociated	NULL
from	NULL
COX	NULL
-independent	NULL
inhibition	NULL
of	NULL
IL-4	NULL
expression	NULL
,	NULL
in	NULL
analogy	NULL
with	NULL
results	NULL
of	NULL
previous	NULL
studies	NULL
of	NULL
COX-2	NULL
gene	NULL
regulation	NULL
.	NULL
``	NULL

''	NULL
``	NULL
Taken	NULL
together	NULL
,	NULL
our	NULL
observations	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
idea	NULL
that	NULL
a	NULL
previously	NULL
unrecognized	NULL
transcriptional	NULL
target	NULL
accounts	NULL
for	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
salicylates	NULL
on	NULL
IL-4	NULL
expression	NULL
.	NULL

In	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
evidence	NULL
suggests	NULL
that	NULL
the	NULL
proximal	NULL
88	NULL
bp	NULL
of	NULL
the	NULL
IL-4	NULL
promoter	NULL
,	NULL
including	NULL
the	NULL
NFAT-binding	NULL
PO	NULL
and	NULL
P1	NULL
elements	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
,	NULL
are	NULL
sufficient	NULL
to	NULL
mediate	NULL
proper	NULL
lineage-restricted	NULL
and	NULL
mito-gen-	NULL
or	NULL
antigen-induced	NULL
IL-4	NULL
expression	NULL
in	NULL
distinct	NULL
Th	NULL
subsets	NULL
.	NULL
``	NULL

However	NULL
,	NULL
our	NULL
finding	NULL
that	NULL
IL-4	NULL
gene	NULL
inhibition	NULL
by	NULL
salicylates	NULL
involves	NULL
DNA-protein	NULL
interactions	NULL
in	NULL
a	NULL
region	NULL
upstream	NULL
of	NULL
bp	NULL
-95	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
idea	NULL
that	NULL
multiple	NULL
promoter	NULL
elements	NULL
contribute	NULL
to	NULL
IL-4	NULL
gene	NULL
activation	NULL
in	NULL
differentiated	NULL
T	NULL
cells.3	NULL
>	NULL
354344	NULL
We	NULL
found	NULL
that	NULL
ASA	NULL
affects	NULL
formation	NULL
of	NULL
an	NULL
inducible	NULL
complex	NULL
on	NULL
a	NULL
discrete	NULL
region	NULL
of	NULL
the	NULL
human	NULL
IL-4	NULL
promoter	NULL
between	NULL
bp	NULL
-135	NULL
and	NULL
-110	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
our	NULL
findings	NULL
and	NULL
sequence	NULL
homology	NULL
,	NULL
we	NULL
infer	NULL
that	NULL
an	NULL
Ets	NULL
family	NULL
member	NULL
other	NULL
than	NULL
Ets-1	NULL
and	NULL
Ets-2	NULL
,	NULL
a	NULL
zinc-finger	NULL
protein	NULL
such	NULL
as	NULL
ZEB	NULL
,	NULL
or	NULL
both	NULL
,	NULL
may	NULL
contribute	NULL
critically	NULL
to	NULL
formation	NULL
of	NULL
this	NULL
complex	NULL
.	NULL
``	NULL

Although	NULL
this	NULL
observation	NULL
provides	NULL
a	NULL
mechanistic	NULL
basis	NULL
for	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
salicylates	NULL
on	NULL
IL-4	NULL
transcription	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
additional	NULL
studies	NULL
are	NULL
necessary	NULL
to	NULL
determine	NULL
the	NULL
precise	NULL
location	NULL
and	NULL
sequence	NULL
of	NULL
a	NULL
discrete	NULL
ASA	NULL
References	NULL
BLOOD	NULL
,	NULL
15	NULL
MARCH	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
6	NULL
responsive	NULL
element	NULL
on	NULL
this	NULL
region	NULL
of	NULL
the	NULL
IL-4	NULL
promoter	NULL
as	NULL
well	NULL
as	NULL
the	NULL
identity	NULL
and	NULL
function	NULL
of	NULL
its	NULL
cognate	NULL
factor	NULL
or	NULL
factors	NULL
.	NULL

IL-4	NULL
,	NULL
the	NULL
prototypic	NULL
cytokine	NULL
expressed	NULL
in	NULL
Th2	NULL
cells	NULL
,	NULL
plays	NULL
a	NULL
pivotal	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
hematopoiesis	NULL
and	NULL
immune	NULL
and	NULL
inflammatory	NULL
responses	NULL
and	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
a	NULL
wide	NULL
spectrum	NULL
of	NULL
disease	NULL
conditions	NULL
.	NULL
``	NULL

''	NULL
Although	NULL
suppression	NULL
of	NULL
Th1	NULL
responses	NULL
by	NULL
means	NULL
of	NULL
NF-KB	NULL
inhibition	NULL
occurs	NULL
at	NULL
ASA	NULL
doses	NULL
well	NULL
above	NULL
the	NULL
therapeutic	NULL
range	NULL
,	NULL
``	NULL
?	NULL
``	NULL

lower	NULL
concentrations	NULL
of	NULL
ASA	NULL
can	NULL
enhance	NULL
(	NULL
by	NULL
means	NULL
of	NULL
inhibition	NULL
of	NULL
monocyte	NULL
PG	NULL
generation	NULL
)	NULL
the	NULL
in	NULL
vitro	NULL
and	NULL
ex	NULL
vivo	NULL
expression	NULL
of	NULL
at	NULL
least	NULL
some	NULL
Th1	NULL
cytokines	NULL
and	NULL
inherently	NULL
counteract	NULL
Th2	NULL
responses	NULL
.	NULL
``	NULL

Therefore	NULL
,	NULL
NSAIDs	NULL
have	NULL
been	NULL
evaluated	NULL
as	NULL
possible	NULL
adjuvants	NULL
of	NULL
Th1-driven	NULL
antiviral	NULL
responses	NULL
'	NULL
``	NULL
``	NULL
``	NULL
and	NULL
in	NULL
the	NULL
management	NULL
of	NULL
Th2-associated	NULL
and	NULL
IL-4-associated	NULL
conditions	NULL
such	NULL
as	NULL
atopic	NULL
asthma	NULL
or	NULL
rhinitis.©	NULL
``	NULL
``	NULL
``	NULL
It	NULL
was	NULL
shown	NULL
that	NULL
topical	NULL
treatment	NULL
with	NULL
lysin-ASA	NULL
or	NULL
SA	NULL
,	NULL
but	NULL
not	NULL
IM	NULL
,	NULL
can	NULL
prevent	NULL
the	NULL
early	NULL
asthmatic	NULL
response	NULL
to	NULL
inhaled	NULL
allergen	NULL
,	NULL
``	NULL
a	NULL
finding	NULL
consistent	NULL
with	NULL
the	NULL
critical	NULL
role	NULL
of	NULL
IL-4	NULL
in	NULL
the	NULL
development	NULL
of	NULL
such	NULL
reactions	NULL
.	NULL
``	NULL

''	NULL
IL-4	NULL
and	NULL
Th2	NULL
responses	NULL
are	NULL
also	NULL
involved	NULL
in	NULL
vernal	NULL
conjunctivitis	NULL
,	NULL
``	NULL
juvenile	NULL
rheumatoid	NULL
arthritis	NULL
,	NULL
``	NULL
Kawasaki	NULL
disease	NULL
,	NULL
``	NULL
``	NULL
and	NULL
other	NULL
conditions	NULL
in	NULL
which	NULL
the	NULL
effectiveness	NULL
of	NULL
salicylates	NULL
is	NULL
well	NULL
documented	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
Our	NULL
study	NULL
,	NULL
which	NULL
showed	NULL
direct	NULL
inhibition	NULL
of	NULL
IL-4	NULL
production	NULL
in	NULL
T	NULL
cells	NULL
independent	NULL
of	NULL
COX	NULL
and	NULL
NF-KB	NULL
activity	NULL
,	NULL
provides	NULL
a	NULL
new	NULL
rationale	NULL
for	NULL
and	NULL
creates	NULL
new	NULL
perspectives	NULL
on	NULL
the	NULL
therapeutic	NULL
applications	NULL
of	NULL
ASA	NULL
and	NULL
related	NULL
compounds	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Drs	NULL
Gerald	NULL
R.	NULL
Crabtree	NULL
and	NULL
Jack	NULL
L.	NULL
Strominger	NULL
for	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
reagents	NULL
;	NULL
Drs	NULL
Susan	NULL
M.	NULL
MacDonald	NULL
,	NULL
Robert	NULL
P.	NULL
Schleimer	NULL
,	NULL
and	NULL
Bradley	NULL
J.	NULL
Undem	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
;	NULL
and	NULL
Drs	NULL
Bruce	NULL
S.	NULL
Bochner	NULL
,	NULL
Katsushi	NULL
Miura	NULL
,	NULL
and	NULL
Cristiana	NULL
Stellato	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
comments	NULL
.	NULL

.	NULL

Goodnight	NULL
SH	NULL
.	NULL

Antiplatelet	NULL
therapy	NULL
with	NULL
aspirin	NULL
:	NULL
from	NULL
clinical	NULL
trials	NULL
to	NULL
practice	NULL
.	NULL

Thromb	NULL
Haemost	NULL
.	NULL

1995	NULL
;	NULL
74:401-405.	NULL
.	NULL

Gupta	NULL
RA	NULL
,	NULL
DuBois	NULL
RN	NULL
.	NULL

Aspirin	NULL
,	NULL
NSAIDs	NULL
,	NULL
and	NULL
colon	NULL
cancer	NULL
prevention	NULL
:	NULL
mechanisms	NULL
?	NULL

Gastroen-terology	NULL
.	NULL

1998	NULL
;	NULL
114:1095-1098.	NULL
.	NULL

Vane	NULL
JR.	NULL
Inhibition	NULL
of	NULL
prostaglandin	NULL
synthesis	NULL
as	NULL
a	NULL
mechanism	NULL
of	NULL
action	NULL
for	NULL
aspirin-like	NULL
drugs	NULL
.	NULL

Nat	NULL
New	NULL
Biol	NULL
.	NULL

1971	NULL
;	NULL
231:232-235.	NULL
.	NULL

Vane	NULL
JR	NULL
,	NULL
Botting	NULL
RM	NULL
.	NULL

Mechanism	NULL
of	NULL
action	NULL
of	NULL
nonsteroidal	NULL
anti-inflammatory	NULL
drugs	NULL
.	NULL

Am	NULL
J	NULL
Med	NULL
.	NULL

1998	NULL
;	NULL
104:25-8S	NULL
.	NULL

.	NULL

Mitchell	NULL
JA	NULL
,	NULL
Akarasereenont	NULL
P	NULL
,	NULL
Thiemermann	NULL
C	NULL
,	NULL
Flower	NULL
RJ	NULL
,	NULL
Vane	NULL
JR.	NULL
Selectivity	NULL
of	NULL
nonsteroidal	NULL
antiinflammatory	NULL
drugs	NULL
as	NULL
inhibitors	NULL
of	NULL
constitutive	NULL
and	NULL
inducible	NULL
cyclooxygenase	NULL
.	NULL

Proc	NULL
Nat	NULL
!	NULL

Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1994	NULL
;	NULL
90:11693-11697.	NULL
.	NULL

Abramson	NULL
SB	NULL
,	NULL
Weissmann	NULL
G.	NULL
The	NULL
mechanisms	NULL
of	NULL
action	NULL
of	NULL
nonsteroidal	NULL
antiinflammatory	NULL
drugs	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

1989	NULL
;	NULL
32:1-9.	NULL
.	NULL

Bombardier	NULL
C	NULL
,	NULL
Peloso	NULL
PM	NULL
,	NULL
Goldsmith	NULL
CH	NULL
.	NULL

Sal-salate	NULL
,	NULL
a	NULL
nonacetylated	NULL
salicylate	NULL
,	NULL
is	NULL
as	NULL
efficacious	NULL
as	NULL
diclofenac	NULL
in	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Salsalate-Diclofenac	NULL
Study	NULL
Group	NULL
.	NULL

J	NULL
Rheumatol	NULL
.	NULL

1995	NULL
;	NULL
22:617-624.	NULL
.	NULL

Kopp	NULL
E	NULL
,	NULL
Ghosh	NULL
S.	NULL
Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
sodium	NULL
salicylate	NULL
and	NULL
aspirin	NULL
.	NULL

Science	NULL
.	NULL

1994	NULL
;	NULL
265:956-959.	NULL
.	NULL

Cronstein	NULL
BN	NULL
,	NULL
Montesinos	NULL
MC	NULL
,	NULL
Weissmann	NULL
G.	NULL
Salicylates	NULL
and	NULL
sulfasalazine	NULL
,	NULL
but	NULL
not	NULL
glucocorti-coids	NULL
,	NULL
inhibit	NULL
leukocyte	NULL
accumulation	NULL
by	NULL
an	NULL
aden-osine-dependent	NULL
mechanism	NULL
that	NULL
is	NULL
independent	NULL
of	NULL
inhibition	NULL
of	NULL
prostaglandin	NULL
synthesis	NULL
and	NULL
p105	NULL
of	NULL
NFkB	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1999	NULL
;	NULL
96	NULL
:	NULL
6377-6381.	NULL
.	NULL

Dong	NULL
Z	NULL
,	NULL
Huang	NULL
C	NULL
,	NULL
Brown	NULL
RE	NULL
,	NULL
Ma	NULL
WY	NULL
.	NULL

Inhibition	NULL
of	NULL
activator	NULL
protein	NULL
1	NULL
activity	NULL
and	NULL
neoplastic	NULL
transformation	NULL
by	NULL
aspirin	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

1997	NULL
;	NULL
272	NULL
:	NULL
9962-9970	NULL
.	NULL

Farivar	NULL
RS	NULL
,	NULL
Brecher	NULL
P.	NULL
Salicylate	NULL
is	NULL
a	NULL
transcriptional	NULL
inhibitor	NULL
of	NULL
the	NULL
inducible	NULL
nitric	NULL
oxide	NULL
syn-thase	NULL
in	NULL
cultured	NULL
cardiac	NULL
fibroblasts	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

1996	NULL
;	NULL
271:31585-31592.	NULL
.	NULL

Sakitani	NULL
K	NULL
,	NULL
Kitade	NULL
H	NULL
,	NULL
Inoue	NULL
K	NULL
,	NULL
et	NULL
al	NULL
.	NULL

The	NULL
anti-in-	NULL
flammatory	NULL
drug	NULL
sodium	NULL
salicylate	NULL
inhibits	NULL
nitric	NULL
oxide	NULL
formation	NULL
induced	NULL
by	NULL
interleukin-18	NULL
at	NULL
a	NULL
translational	NULL
step	NULL
,	NULL
but	NULL
not	NULL
at	NULL
a	NULL
transcriptional	NULL
step	NULL
,	NULL
in	NULL
hepatocytes	NULL
.	NULL

Hepatology	NULL
.	NULL

1997	NULL
;	NULL
25:416-420	NULL
.	NULL

J	NULL
.	NULL

1999	NULL
;	NULL
342:503-507	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1997	NULL
;	NULL
185:1693-1704	NULL
.	NULL

2389-2398.	NULL
.	NULL

Schwenger	NULL
P	NULL
,	NULL
Alpert	NULL
D	NULL
,	NULL
Skolnik	NULL
EY	NULL
,	NULL
Vilcek	NULL
J	NULL
.	NULL

Cell	NULL
type-specific	NULL
activation	NULL
of	NULL
c-Jun	NULL
N-terminal	NULL
kinase	NULL
by	NULL
salicylates	NULL
.	NULL

J	NULL
Cell	NULL
Physiol	NULL
.	NULL

1999	NULL
;	NULL
179:109-114	NULL
.	NULL

20	NULL
.	NULL

Giambartolomei	NULL
S	NULL
,	NULL
Artini	NULL
M	NULL
,	NULL
Almerighi	NULL
C	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Nonsteroidal	NULL
anti-inflammatory	NULL
drug	NULL
metabolism	NULL
potentiates	NULL
interferon	NULL
alfa	NULL
signaling	NULL
by	NULL
increasing	NULL
STATA	NULL
phosphorylation	NULL
.	NULL

Hepatology	NULL
.	NULL

1999	NULL
;	NULL
30	NULL
:	NULL
510-516	NULL
.	NULL

Goodwin	NULL
JS	NULL
,	NULL
Ceuppens	NULL
JL	NULL
.	NULL

Effect	NULL
of	NULL
nonsteroidal	NULL
antiinflammatory	NULL
drugs	NULL
on	NULL
immune	NULL
function	NULL
.	NULL

Se-min	NULL
Arthritis	NULL
Rheum	NULL
.	NULL

1983	NULL
;	NULL
13:134-143	NULL
.	NULL

Betz	NULL
M	NULL
,	NULL
Fox	NULL
BS	NULL
.	NULL

Prostaglandin	NULL
E	NULL
;	NULL
inhibits	NULL
production	NULL
of	NULL
Th1	NULL
lymphokines	NULL
but	NULL
not	NULL
of	NULL
Th2	NULL
lympho-kines	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1991	NULL
;	NULL
146:108-113	NULL
.	NULL

Demeure	NULL
CE	NULL
,	NULL
Yang	NULL
LP	NULL
,	NULL
Desjardins	NULL
C	NULL
,	NULL
Raynauld	NULL
P	NULL
,	NULL
Delespesse	NULL
G.	NULL
Prostaglandin	NULL
E	NULL
;	NULL
primes	NULL
naive	NULL
T	NULL
cells	NULL
for	NULL
the	NULL
production	NULL
of	NULL
anti-inflammatory	NULL
cy-tokines	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
.	NULL

1997	NULL
;	NULL
27:3526-3531	NULL
.	NULL

21	NULL
.	NULL

Flescher	NULL
E	NULL
,	NULL
Fossum	NULL
D	NULL
,	NULL
Gray	NULL
PJ	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Aspirin-like	NULL
.	NULL

Chen	NULL
LC	NULL
,	NULL
Kepka-Lenhart	NULL
D	NULL
,	NULL
Wright	NULL
TM	NULL
,	NULL
Morris	NULL
drugs	NULL
prime	NULL
human	NULL
T	NULL
cells	NULL
:	NULL
modulation	NULL
of	NULL
intra-SM	NULL
Jr.	NULL
Salicylate-enhanced	NULL
activation	NULL
of	NULL
tran-	NULL
cellular	NULL
calcium	NULL
concentrations	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1991	NULL
;	NULL
scription	NULL
factors	NULL
induced	NULL
by	NULL
interferon-y	NULL
.	NULL

Biochem	NULL
146:2553-2559	NULL
.	NULL

22	NULL
.	NULL

Hsia	NULL
J	NULL
,	NULL
Sarin	NULL
N	NULL
,	NULL
Oliver	NULL
JH	NULL
,	NULL
Goldstein	NULL
AL	NULL
.	NULL

Aspirin	NULL
.	NULL

Takano	NULL
T	NULL
,	NULL
Fiore	NULL
S	NULL
,	NULL
Maddox	NULL
JF	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Aspirin-trig-	NULL
and	NULL
thymosin	NULL
increase	NULL
interleukin-2	NULL
and	NULL
inter-gered	NULL
15-epi-lipoxin	NULL
A	NULL
,	NULL
(	NULL
LXA	NULL
,	NULL
)	NULL
and	NULL
stable	NULL
feron-gamma	NULL
production	NULL
by	NULL
human	NULL
peripheral	NULL
analogues	NULL
are	NULL
potent	NULL
inhibitors	NULL
of	NULL
acute	NULL
inflam-	NULL
blood	NULL
lymphocytes	NULL
.	NULL

Immunopharmacology	NULL
.	NULL

1989	NULL
;	NULL
mation	NULL
:	NULL
evidence	NULL
for	NULL
anti-inflammatory	NULL
receptors	NULL
.	NULL

17:167-173	NULL
.	NULL

23	NULL
.	NULL

Endres	NULL
S	NULL
,	NULL
Whitaker	NULL
RE	NULL
,	NULL
Ghorbani	NULL
R	NULL
,	NULL
Meydani	NULL
.	NULL

Gerli	NULL
R	NULL
,	NULL
Paolucci	NULL
C	NULL
,	NULL
Gresele	NULL
P	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Salicylates	NULL
SN	NULL
,	NULL
Dinarello	NULL
CA	NULL
.	NULL

Oral	NULL
aspirin	NULL
and	NULL
ibuprofen	NULL
in-inhibit	NULL
adhesion	NULL
and	NULL
transmigration	NULL
of	NULL
T	NULL
lympho-	NULL
crease	NULL
cytokine-induced	NULL
synthesis	NULL
of	NULL
IL-1	NULL
and	NULL
of	NULL
cytes	NULL
by	NULL
preventing	NULL
integrin	NULL
activation	NULL
induced	NULL
by	NULL
tumour	NULL
necrosis	NULL
factor-	NULL
«	NULL
ex	NULL
vivo	NULL
.	NULL

Immunology	NULL
.	NULL

contact	NULL
with	NULL
endothelial	NULL
cells	NULL
.	NULL

Blood	NULL
.	NULL

1998	NULL
;	NULL
92	NULL
;	NULL
1996	NULL
;	NULL
87:264-270	NULL
.	NULL

24	NULL
.	NULL

Tsuboi	NULL
|	NULL
,	NULL
Tanaka	NULL
H	NULL
,	NULL
Nakao	NULL
M	NULL
,	NULL
Shichijo	NULL
S	NULL
,	NULL
Itoh	NULL
K.	NULL
Nonsteroidal	NULL
anti-inflammatory	NULL
drugs	NULL
differentially	NULL
regulate	NULL
cytokine	NULL
production	NULL
in	NULL
human	NULL
lymphocytes	NULL
:	NULL
up-regulation	NULL
of	NULL
TNF	NULL
,	NULL
IFN-y	NULL
and	NULL
IL-2	NULL
,	NULL
in	NULL
BLOOD	NULL
,	NULL
15	NULL
MARCH	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
6	NULL
25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

286	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

contrast	NULL
to	NULL
down-regulation	NULL
of	NULL
IL-6	NULL
production	NULL
.	NULL

Cytokine	NULL
.	NULL

1995	NULL
;	NULL
7:372-379	NULL
.	NULL

Weber	NULL
C	NULL
,	NULL
Erl	NULL
W	NULL
,	NULL
Pietsch	NULL
A	NULL
,	NULL
Weber	NULL
PC	NULL
.	NULL

Aspirin	NULL
inhibits	NULL
nuclear	NULL
factor-	NULL
«	NULL
B	NULL
mobilization	NULL
and	NULL
monocyte	NULL
adhesion	NULL
in	NULL
stimulated	NULL
human	NULL
endothelial	NULL
cells	NULL
.	NULL

Circulation	NULL
.	NULL

1995	NULL
;	NULL
91:1914-1917	NULL
.	NULL

Mazzeo	NULL
D	NULL
,	NULL
Panina-Bordignon	NULL
P	NULL
,	NULL
Recalde	NULL
H	NULL
,	NULL
Sini-gaglia	NULL
F	NULL
,	NULL
D'Ambrosio	NULL
D.	NULL
Decreased	NULL
IL-12	NULL
production	NULL
and	NULL
Th1	NULL
cell	NULL
development	NULL
by	NULL
acetyl	NULL
salicylic	NULL
acid-mediated	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
.	NULL

1998	NULL
;	NULL
28:3205-3213	NULL
.	NULL

Pierce	NULL
JW	NULL
,	NULL
Read	NULL
MA	NULL
,	NULL
Ding	NULL
H	NULL
,	NULL
Luscinskas	NULL
FW	NULL
,	NULL
Collins	NULL
T.	NULL
Salicylates	NULL
inhibit	NULL
IkB-	NULL
«	NULL
phosphoryla-tion	NULL
,	NULL
endothelial-leukocyte	NULL
adhesion	NULL
molecule	NULL
expression	NULL
,	NULL
and	NULL
neutrophil	NULL
transmigration	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1996	NULL
;	NULL
156:3961-3969	NULL
.	NULL

Neumann	NULL
M	NULL
,	NULL
Grieshammer	NULL
T	NULL
,	NULL
Chuypilo	NULL
S	NULL
,	NULL
et	NULL
al	NULL
.	NULL

RelA/p65	NULL
is	NULL
a	NULL
molecular	NULL
target	NULL
for	NULL
the	NULL
immuno-suppressive	NULL
action	NULL
of	NULL
protein	NULL
kinase	NULL
A.	NULL
EMBO	NULL
J	NULL
.	NULL

1995	NULL
;	NULL
14:1991-2004	NULL
.	NULL

Lederer	NULL
JA	NULL
,	NULL
Liou	NULL
JS	NULL
,	NULL
Todd	NULL
MD	NULL
,	NULL
Glimcher	NULL
LH	NULL
,	NULL
Li-chtman	NULL
AH	NULL
.	NULL

Regulation	NULL
of	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
helper	NULL
cell	NULL
subsets	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1994	NULL
;	NULL
152:77-86	NULL
.	NULL

Casolaro	NULL
V	NULL
,	NULL
Georas	NULL
SN	NULL
,	NULL
Song	NULL
Z	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-AT-dependent	NULL
transcription	NULL
by	NULL
NF-kB	NULL
:	NULL
implications	NULL
for	NULL
differential	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
helper	NULL
cell	NULL
subsets	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1995	NULL
;	NULL
92:11623-11627	NULL
.	NULL

Schroeder	NULL
JT	NULL
,	NULL
Howard	NULL
BP	NULL
,	NULL
Jenkens	NULL
MK	NULL
,	NULL
et	NULL
al	NULL
.	NULL

IL-4	NULL
secretion	NULL
and	NULL
histamine	NULL
release	NULL
by	NULL
human	NULL
basophils	NULL
are	NULL
differentially	NULL
regulated	NULL
by	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
.	NULL

J	NULL
Leukoc	NULL
Biol	NULL
.	NULL

1998	NULL
;	NULL
63:692-698	NULL
.	NULL

Freeman	NULL
WM	NULL
,	NULL
Walker	NULL
SJ	NULL
,	NULL
Vrana	NULL
KE	NULL
.	NULL

Quantitative	NULL
RT-PCR	NULL
:	NULL
pitfalls	NULL
and	NULL
potential	NULL
.	NULL

Biotechniques	NULL
.	NULL

1999	NULL
;	NULL
26:112-125	NULL
.	NULL

Georas	NULL
S	NULL
,	NULL
Cumberland	NULL
J	NULL
,	NULL
Burke	NULL
T	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
novel	NULL
negative	NULL
regulatory	NULL
element	NULL
in	NULL
the	NULL
human	NULL
interleukin	NULL
4	NULL
promoter	NULL
.	NULL

Leukemia	NULL
.	NULL

2000	NULL
;	NULL
14:629-635	NULL
.	NULL

Durand	NULL
DB	NULL
,	NULL
Shaw	NULL
JP	NULL
,	NULL
Bush	NULL
MR	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin-2	NULL
enhancer	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1988	NULL
;	NULL
8:1715-1724	NULL
.	NULL

Georas	NULL
SN	NULL
,	NULL
Cumberland	NULL
JE	NULL
,	NULL
Burke	NULL
TF	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Stat6	NULL
inhibits	NULL
human	NULL
interleukin-4	NULL
promoter	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Blood	NULL
.	NULL

1998	NULL
;	NULL
92:4529-4538	NULL
.	NULL

Pablos	NULL
JL	NULL
,	NULL
Santiago	NULL
B	NULL
,	NULL
Carreira	NULL
PE	NULL
,	NULL
Galindo	NULL
M	NULL
,	NULL
Gomez-Reino	NULL
JJ	NULL
.	NULL

Cyclooxygenase-1	NULL
and	NULL
-2	NULL
are	NULL
expressed	NULL
by	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Clin	NULL
Exp	NULL
Immunol	NULL
.	NULL

1999	NULL
;	NULL
115:86-90	NULL
.	NULL

Furst	NULL
DE	NULL
,	NULL
Blocka	NULL
K	NULL
,	NULL
Cassell	NULL
S	NULL
,	NULL
et	NULL
al	NULL
.	NULL

A	NULL
strategy	NULL
for	NULL
reaching	NULL
therapeutic	NULL
salicylate	NULL
levels	NULL
in	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
using	NULL
standardized	NULL
dosing	NULL
regimens	NULL
.	NULL

J	NULL
Rheumatol	NULL
.	NULL

1987	NULL
;	NULL
14:342-347	NULL
.	NULL

Seder	NULL
RA	NULL
,	NULL
Paul	NULL
WE	NULL
,	NULL
Davis	NULL
MM	NULL
,	NULL
Fazekas	NULL
de	NULL
St	NULL
Groth	NULL
B	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
interleukin	NULL
4	NULL
during	NULL
in	NULL
vitro	NULL
priming	NULL
determines	NULL
the	NULL
lymphokine-produc-ing	NULL
potential	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
T	NULL
cell	NULL
receptor	NULL
transgenic	NULL
mice	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1992	NULL
;	NULL
176:1091-1098	NULL
.	NULL

Zhang	NULL
G	NULL
,	NULL
Gurtu	NULL
V	NULL
,	NULL
Kain	NULL
SR	NULL
,	NULL
Yan	NULL
G.	NULL
Early	NULL
detection	NULL
of	NULL
apoptosis	NULL
using	NULL
a	NULL
fluorescent	NULL
conjugate	NULL
of	NULL
annexin	NULL
V.	NULL
Biotechniques	NULL
.	NULL

1997	NULL
;	NULL
23:525-531	NULL
.	NULL

Wahl	NULL
C	NULL
,	NULL
Liptay	NULL
S	NULL
,	NULL
Adler	NULL
G	NULL
,	NULL
Schmid	NULL
RM	NULL
.	NULL

Sulfasala-zing	NULL
:	NULL
a	NULL
potent	NULL
and	NULL
specific	NULL
inhibitor	NULL
of	NULL
nuclear	NULL
factor	NULL
kB	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

1998	NULL
;	NULL
101:1163-1174	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

INHIBITION	NULL
OF	NULL
T-CELL	NULL
IL-4	NULL
EXPRESSION	NULL
BY	NULL
ASPIRIN	NULL
Sen	NULL
R	NULL
,	NULL
Baltimore	NULL
D.	NULL
inducibility	NULL
of	NULL
x	NULL
immunoglobulin	NULL
enhancer-binding	NULL
protein	NULL
NF-B	NULL
by	NULL
a	NULL
posttranslational	NULL
mechanism	NULL
.	NULL

Cell	NULL
.	NULL

1986	NULL
;	NULL
47:921-928	NULL
.	NULL

Haynes	NULL
DR	NULL
,	NULL
Wright	NULL
PF	NULL
,	NULL
Gadd	NULL
SJ	NULL
,	NULL
Whitehouse	NULL
MW	NULL
,	NULL
Vernon-Roberts	NULL
B	NULL
.	NULL

Is	NULL
aspirin	NULL
a	NULL
prodrug	NULL
for	NULL
antioxidant	NULL
and	NULL
cytokine-modulating	NULL
oxymetabo-lites	NULL
?	NULL

Agents	NULL
Actions	NULL
.	NULL

1993	NULL
;	NULL
39:49-58	NULL
.	NULL

Szabo	NULL
SJ	NULL
,	NULL
Gold	NULL
JS	NULL
,	NULL
Murphy	NULL
TL	NULL
,	NULL
Murphy	NULL
KM	NULL
.	NULL

Identification	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
elements	NULL
controlling	NULL
interleukin-4	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
:	NULL
roles	NULL
for	NULL
NF-Y	NULL
and	NULL
NF-ATc	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1993	NULL
;	NULL
13:4793-4805	NULL
.	NULL

Li-Weber	NULL
M	NULL
,	NULL
Davydov	NULL
IV	NULL
,	NULL
Krafft	NULL
H	NULL
,	NULL
Krammer	NULL
PH	NULL
.	NULL

The	NULL
role	NULL
of	NULL
NF-Y	NULL
and	NULL
IRF-2	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
human	NULL
IL-4	NULL
gene	NULL
expression	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1994	NULL
;	NULL
153:4122-4133	NULL
.	NULL

Romano-Spica	NULL
V	NULL
,	NULL
Georgiou	NULL
P	NULL
,	NULL
Suzuki	NULL
H	NULL
,	NULL
Papas	NULL
TS	NULL
,	NULL
Bhat	NULL
NK	NULL
.	NULL

Role	NULL
of	NULL
ETS1	NULL
in	NULL
IL-2	NULL
gene	NULL
expression	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1995	NULL
;	NULL
154:2724-2732	NULL
.	NULL

Heemskerk	NULL
MH	NULL
,	NULL
Blom	NULL
B	NULL
,	NULL
Nolan	NULL
G	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Inhibition	NULL
of	NULL
T	NULL
cell	NULL
and	NULL
promotion	NULL
of	NULL
natural	NULL
killer	NULL
cell	NULL
development	NULL
by	NULL
the	NULL
dominant	NULL
negative	NULL
helix	NULL
loop	NULL
helix	NULL
factor	NULL
Id3	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1997	NULL
;	NULL
186:1597-1602	NULL
.	NULL

Yasui	NULL
DH	NULL
,	NULL
Genetta	NULL
T	NULL
,	NULL
Kadesch	NULL
T	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Transcriptional	NULL
repression	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
in	NULL
Th	NULL
cells	NULL
by	NULL
ZEB	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1998	NULL
;	NULL
160:4433-4440	NULL
.	NULL

Crabtree	NULL
GR	NULL
,	NULL
Clipstone	NULL
NA	NULL
.	NULL

Signal	NULL
transmission	NULL
between	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
nucleus	NULL
of	NULL
T.	NULL
lymphocytes	NULL
.	NULL

Annu	NULL
Rev	NULL
Biochem	NULL
.	NULL

1994	NULL
;	NULL
63:1045-1083	NULL
.	NULL

Flescher	NULL
E	NULL
,	NULL
Ledbetter	NULL
JA	NULL
,	NULL
Ogawa	NULL
N	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Induction	NULL
of	NULL
transcription	NULL
factors	NULL
in	NULL
human	NULL
T	NULL
lympho-cytes	NULL
by	NULL
aspirin-like	NULL
drugs	NULL
.	NULL

Cell	NULL
Immunol	NULL
.	NULL

1995	NULL
;	NULL
160:232-239	NULL
.	NULL

Rooney	NULL
JW	NULL
,	NULL
Hodge	NULL
MR	NULL
,	NULL
McCaffrey	NULL
PG	NULL
,	NULL
Rao	NULL
A	NULL
,	NULL
Glimcher	NULL
LH	NULL
.	NULL

A	NULL
common	NULL
factor	NULL
regulates	NULL
both	NULL
Th1-	NULL
and	NULL
Th2-specific	NULL
cytokine	NULL
gene	NULL
expression	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

1994	NULL
;	NULL
13:625-633	NULL
.	NULL

Van	NULL
der	NULL
Pouw-Kraan	NULL
T	NULL
,	NULL
Van	NULL
Kooten	NULL
C	NULL
,	NULL
Rensink	NULL
1	NULL
,	NULL
Aarden	NULL
L.	NULL
Interleukin	NULL
(	NULL
IL	NULL
)	NULL
-4	NULL
production	NULL
by	NULL
human	NULL
T	NULL
cells	NULL
:	NULL
differential	NULL
regulation	NULL
of	NULL
IL-4	NULL
vs	NULL
IL-2	NULL
production	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
.	NULL

1992	NULL
;	NULL
22:1237-1241	NULL
.	NULL

Kang	NULL
SM	NULL
,	NULL
Tran	NULL
AC	NULL
,	NULL
Grilli	NULL
M	NULL
,	NULL
Lenardo	NULL
MJ	NULL
.	NULL

NF-kB	NULL
subunit	NULL
regulation	NULL
in	NULL
nontransformed	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
.	NULL

Science	NULL
.	NULL

1992	NULL
;	NULL
256:1452-1456	NULL
.	NULL

Brown	NULL
MA	NULL
,	NULL
Hural	NULL
J	NULL
.	NULL

Functions	NULL
of	NULL
IL-4	NULL
and	NULL
control	NULL
of	NULL
its	NULL
expression	NULL
.	NULL

Crit	NULL
Rev	NULL
Immunol	NULL
.	NULL

1997	NULL
;	NULL
17	NULL
:	NULL
1-32	NULL
.	NULL

Rao	NULL
A.	NULL
NF-ATp	NULL
:	NULL
a	NULL
transcription	NULL
factor	NULL
required	NULL
for	NULL
the	NULL
co-ordinate	NULL
induction	NULL
of	NULL
several	NULL
cytokine	NULL
genes	NULL
.	NULL

Immunol	NULL
Today	NULL
.	NULL

1994	NULL
;	NULL
15:274-281	NULL
.	NULL

Rincon	NULL
M	NULL
,	NULL
Flavell	NULL
RA	NULL
.	NULL

Transcription	NULL
mediated	NULL
by	NULL
NFAT	NULL
is	NULL
highly	NULL
inducible	NULL
in	NULL
effector	NULL
CD4*	NULL
T	NULL
helper	NULL
2	NULL
(	NULL
Th2	NULL
)	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
Th1	NULL
cells	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1997	NULL
;	NULL
17:1522-1534	NULL
.	NULL

Dolganov	NULL
G	NULL
,	NULL
Bort	NULL
S	NULL
,	NULL
Loveit	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Coexpres-sion	NULL
of	NULL
the	NULL
interleukin-13	NULL
and	NULL
interleukin-4	NULL
genes	NULL
correlates	NULL
with	NULL
their	NULL
physical	NULL
linkage	NULL
in	NULL
the	NULL
cytokine	NULL
gene	NULL
cluster	NULL
on	NULL
human	NULL
chromosome	NULL
5q23-31	NULL
.	NULL

Blood	NULL
.	NULL

1996	NULL
;	NULL
87:3316-3326	NULL
.	NULL

O'Keefe	NULL
SJ	NULL
,	NULL
Tamura	NULL
J	NULL
,	NULL
Kincaid	NULL
RL	NULL
,	NULL
Tocci	NULL
MJ	NULL
,	NULL
O'Neill	NULL
EA	NULL
.	NULL

FK-506-	NULL
and	NULL
CsA-sensitive	NULL
activation	NULL
of	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
by	NULL
calcineurin	NULL
.	NULL

Na-ture	NULL
.	NULL

1992	NULL
;	NULL
357:692-694	NULL
.	NULL

Cianferoni	NULL
A	NULL
,	NULL
Schroeder	NULL
JT	NULL
,	NULL
Clancy	NULL
Keen	NULL
J	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Dissociation	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
salicylates	NULL
on	NULL
IL-4	NULL
gene	NULL
expression	NULL
and	NULL
NFAT	NULL
activation	NULL
in	NULL
human	NULL
T	NULL
59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67.	NULL
a	NULL
69	NULL
.	NULL

70	NULL
.	NULL

71	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

74	NULL
.	NULL

75	NULL
.	NULL

76	NULL
.	NULL

1749	NULL
cells	NULL
.	NULL

J	NULL
Allergy	NULL
Clin	NULL
Immunol	NULL
.	NULL

2000	NULL
;	NULL
105:5158-	NULL
$	NULL
159	NULL
.	NULL

Xu	NULL
XM	NULL
,	NULL
Sansores-Garcia	NULL
L	NULL
,	NULL
Chen	NULL
XM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Suppression	NULL
of	NULL
inducible	NULL
cyclooxygenase	NULL
2	NULL
gene	NULL
transcription	NULL
by	NULL
aspirin	NULL
and	NULL
sodium	NULL
salicylate	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1999	NULL
;	NULL
96:5292-5297	NULL
.	NULL

Iiguez	NULL
MA	NULL
,	NULL
Punzon	NULL
C	NULL
,	NULL
Fresno	NULL
M.	NULL
Induction	NULL
of	NULL
cyclooxygenase-2	NULL
on	NULL
activated	NULL
T	NULL
lymphocytes	NULL
:	NULL
regulation	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
by	NULL
cyclooxygenase-2	NULL
inhibitors	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1999	NULL
;	NULL
163:111-119	NULL
.	NULL

Wenner	NULL
CA	NULL
,	NULL
Szabo	NULL
SJ	NULL
,	NULL
Murphy	NULL
KM	NULL
.	NULL

Identification	NULL
of	NULL
IL-4	NULL
promoter	NULL
elements	NULL
conferring	NULL
Th2-re-stricted	NULL
expression	NULL
during	NULL
T	NULL
helper	NULL
cell	NULL
subset	NULL
development	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1997	NULL
;	NULL
158:765-773	NULL
.	NULL

Casolaro	NULL
V	NULL
,	NULL
Georas	NULL
SN	NULL
,	NULL
Song	NULL
Z	NULL
,	NULL
Ono	NULL
SJ	NULL
.	NULL

Biclogy	NULL
and	NULL
genetics	NULL
of	NULL
atopic	NULL
disease	NULL
.	NULL

Curr	NULL
Opin	NULL
Immunol	NULL
.	NULL

1996	NULL
;	NULL
8:796-803	NULL
.	NULL

O'Garra	NULL
A.	NULL
Cytokines	NULL
induce	NULL
the	NULL
development	NULL
of	NULL
functionally	NULL
heterogeneous	NULL
T	NULL
helper	NULL
cell	NULL
subsets	NULL
.	NULL

Immunity	NULL
.	NULL

1998	NULL
;	NULL
8:275-283	NULL
.	NULL

Mueller	NULL
R	NULL
,	NULL
Krahl	NULL
T	NULL
,	NULL
Sarveinick	NULL
N.	NULL
Pancreatic	NULL
expression	NULL
of	NULL
interleukin-4	NULL
abrogates	NULL
insulitis	NULL
and	NULL
autoimmune	NULL
diabetes	NULL
in	NULL
nonobese	NULL
diabetic	NULL
(	NULL
NOD	NULL
)	NULL
mice	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1996	NULL
;	NULL
184:1093-1099	NULL
.	NULL

Sharma	NULL
DP	NULL
,	NULL
Ramsay	NULL
AJ	NULL
,	NULL
Maguire	NULL
DJ	NULL
,	NULL
Rolph	NULL
MS	NULL
,	NULL
Ramshaw	NULL
IA	NULL
.	NULL

Interleukin-4	NULL
mediates	NULL
down	NULL
regulation	NULL
of	NULL
antiviral	NULL
cytokine	NULL
expression	NULL
and	NULL
cyto-toxic	NULL
T-lymphocyte	NULL
responses	NULL
and	NULL
exacerbates	NULL
vaccinia	NULL
virus	NULL
infection	NULL
in	NULL
vivo	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1996	NULL
;	NULL
70	NULL
:	NULL
7103-7107	NULL
.	NULL

Hsia	NULL
J	NULL
,	NULL
Tang	NULL
T	NULL
,	NULL
Parrott	NULL
M	NULL
,	NULL
Rogalla	NULL
K.	NULL
Augmentation	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
to	NULL
influenza	NULL
vaccine	NULL
by	NULL
acetylsalicylic	NULL
acid	NULL
:	NULL
a	NULL
clinical	NULL
trial	NULL
in	NULL
a	NULL
geriatric	NULL
population	NULL
.	NULL

Methods	NULL
Find	NULL
Exp	NULL
Clin	NULL
Pharmacol	NULL
.	NULL

1994	NULL
;	NULL
16:677-683	NULL
.	NULL

Kumar	NULL
P	NULL
,	NULL
Bryan	NULL
C	NULL
,	NULL
Hwang	NULL
D	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Allergic	NULL
rhinitis	NULL
relieved	NULL
by	NULL
aspirin	NULL
and	NULL
other	NULL
nonsteroidal	NULL
antin-flammatory	NULL
drugs	NULL
.	NULL

Ann	NULL
Allergy	NULL
.	NULL

1988	NULL
;	NULL
60:419-422	NULL
.	NULL

Szczeklik	NULL
A	NULL
,	NULL
Nizankowska	NULL
E.	NULL
Asthma	NULL
improved	NULL
by	NULL
aspirin-like	NULL
drugs	NULL
.	NULL

Br	NULL
J	NULL
Dis	NULL
Chest	NULL
.	NULL

1983	NULL
;	NULL
77	NULL
:	NULL
153-158	NULL
.	NULL

Sestini	NULL
P	NULL
,	NULL
Refini	NULL
RM	NULL
,	NULL
Pieroni	NULL
MG	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Different	NULL
effects	NULL
of	NULL
inhaled	NULL
aspirinlike	NULL
drugs	NULL
on	NULL
allergen-induced	NULL
early	NULL
and	NULL
late	NULL
asthmatic	NULL
responses	NULL
.	NULL

Am	NULL
J	NULL
Respir	NULL
Crit	NULL
Care	NULL
Med	NULL
.	NULL

1999	NULL
;	NULL
159:1228-1233	NULL
.	NULL

Henderson	NULL
WR	NULL
Jr	NULL
,	NULL
Chi	NULL
EY	NULL
,	NULL
Maliszewski	NULL
CR	NULL
.	NULL

Soluble	NULL
IL-4	NULL
receptor	NULL
inhibits	NULL
airway	NULL
inflammation	NULL
following	NULL
allergen	NULL
challenge	NULL
in	NULL
a	NULL
mouse	NULL
model	NULL
of	NULL
asthma	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

2000	NULL
;	NULL
164:1086-1095	NULL
.	NULL

Maggi	NULL
E	NULL
,	NULL
Biswas	NULL
P	NULL
,	NULL
Del	NULL
Prete	NULL
G	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Accumulation	NULL
of	NULL
Th-2-like	NULL
helper	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
conjunctiva	NULL
of	NULL
patients	NULL
with	NULL
vernal	NULL
conjunctivitis	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1991	NULL
;	NULL
146:1169-1174	NULL
.	NULL

Raziuddin	NULL
S	NULL
,	NULL
al-Dalaan	NULL
A	NULL
,	NULL
Bahabri	NULL
S	NULL
,	NULL
Siraj	NULL
AK	NULL
,	NULL
al-Sedairy	NULL
S.	NULL
Divergent	NULL
cytokine	NULL
production	NULL
profile	NULL
in	NULL
Behget	NULL
's	NULL
disease	NULL
:	NULL
altered	NULL
Th1/Th2	NULL
cell	NULL
cytokine	NULL
pattern	NULL
.	NULL

J	NULL
Rheumatol	NULL
.	NULL

1998	NULL
;	NULL
25:329-333	NULL
.	NULL

Hirao	NULL
J	NULL
,	NULL
Hibi	NULL
S	NULL
,	NULL
Andoh	NULL
T	NULL
,	NULL
Ichimura	NULL
T.	NULL
High	NULL
levels	NULL
of	NULL
circulating	NULL
interleukin-4	NULL
and	NULL
interleukin-10	NULL
in	NULL
Kawasaki	NULL
disease	NULL
.	NULL

Int	NULL
Arch	NULL
Allergy	NULL
Immunol	NULL
.	NULL

1997	NULL
;	NULL
112:152-156	NULL
.	NULL

Abelson	NULL
MB	NULL
,	NULL
Butrus	NULL
Sl	NULL
,	NULL
Weston	NULL
JH	NULL
.	NULL

Aspirin	NULL
therapy	NULL
in	NULL
vernal	NULL
conjunctivitis	NULL
.	NULL

Am	NULL
J	NULL
Ophthalmol	NULL
.	NULL

1983	NULL
;	NULL
95:502-505	NULL
.	NULL

Rewald	NULL
E	NULL
,	NULL
Jaksic	NULL
JC	NULL
.	NULL

Behcet	NULL
's	NULL
syndrome	NULL
treated	NULL
with	NULL
high-dose	NULL
intravenous	NULL
IgG	NULL
and	NULL
low-dose	NULL
aspirin	NULL
.	NULL

J	NULL
R	NULL
Soc	NULL
Med	NULL
.	NULL

1990	NULL
;	NULL
83:652-653	NULL
.	NULL

Denning	NULL
DW	NULL
.	NULL

Kawasaki	NULL
disease	NULL
and	NULL
aspirin	NULL
.	NULL

Lan-cet	NULL
.	NULL

1983	NULL
;	NULL
2:621	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
2001	NULL
97	NULL
:	NULL
1742-1749	NULL
doi:10.1182/blood.V97.6.1	NULL
742	NULL
Selective	NULL
inhibition	NULL
of	NULL
interleukin-4	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
by	NULL
aspirin	NULL
4	NULL
,	NULL
8	NULL
5	NULL
p	NULL
'	NULL
ﬁ	NULL
'	NULL
f	NULL
)	NULL
..	NULL
os	NULL
2101	NULL
%	NULL
N	NULL
@	NULL
0	NULL
Antonella	NULL
Cianferoni	NULL
,	NULL
John	NULL
T.	NULL
Schroeder	NULL
,	NULL
Jean	NULL
Kim	NULL
,	NULL
John	NULL
W.	NULL
Schmidt	NULL
,	NULL
Lawrence	NULL
M.	NULL
Lichtenstein	NULL
,	NULL
Steve	NULL
N.	NULL
Georas	NULL
and	NULL
Vincenzo	NULL
Casolaro	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/97/6/1742.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Gene	NULL
Expression	NULL
(	NULL
1086	NULL
articles	NULL
)	NULL
Immunobiology	NULL
and	NULL
Immunotherapy	NULL
(	NULL
5678	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

